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CHAPTER I 
 
INTRODUCTION 
 
 Like many common diseases with a genetic basis, the etiology of late-onset 
Alzheimer disease (LOAD) is complex.  Evidence suggests that LOAD is a 
heterogeneous trait with multiple susceptibility loci and possibly gene-gene interactions 
involved.  While there are existing methods that can address specific components of this 
etiology, ultimately, the real power of these methods lies in our ability to marry them into 
a comprehensive approach to genetic analysis, so that their relative strengths and 
weaknesses can be balanced and a range of alternative hypotheses can be investigated.  
Thus, I propose a two-stage, multi-pronged approach to the problem of genetic analysis 
of LOAD in which heterogeneity is first addressed by dissecting-out more homogeneous 
subsets of the data and then main effects and gene-gene interactions are investigated in 
each of these subsets. 
 The theoretical basis for such an approach to the analysis of complex genetic 
diseases is presented in Chapter II.  Definitions and examples of heterogeneity and 
interactions that complicate genetic analysis are presented.  Existing methods for 
detecting heterogeneity and interactions are reviewed, and gaps in methodology are 
discussed. 
 Chapter III presents a simulation study in which the performance of three 
clustering methods is compared in the task of uncovering trait heterogeneity in simulated 
data.  A novel data simulation algorithm is introduced.  The best of the three clustering 
1 
methods—Bayesian Classification—is chosen and its applicability to real data (based on 
its false positive and false negative rates) is investigated. 
Chapter IV details an extension of this simulation study in which the 
implementation of the Bayesian Classification method is modified to improve 
performance under a wider range of conditions realistic for genetic studies.  False 
positive and false negative rates under these conditions are also investigated. 
Chapter V presents an application of the proposed two-stage comprehensive 
analysis to a late-onset Alzheimer disease dataset.  Analysis of heterogeneity is 
performed using the Bayesian Classification clustering method.  Main effect analysis is 
performed in cluster subsets.  For the case-control dataset, the Pearson chi-square test of 
independence is applied, and for the family-based dataset, two-point linkage analysis, the 
Pedigree Disequilibrium Test and the Family-Based Association Test are utilized.  
Interaction analysis is performed using the Multifactor Dimensionality Reduction 
method.  Logistic regression is used to explore the structure of predictive MDR models 
found significant by permutation testing.  Results of these integrated analyses are 
interpreted, and limitations of the study design and analysis methods are discussed. 
In Chapter VI, the entirety of the research comprising this dissertation is put into 
perspective, discussing the lessons learned and the immediate future directions for this 
work.  New directions for future studies of neurogenetic diseases are also discussed and 
suggestions are made as to the focus of future research efforts, given current and 
forthcoming phenotyping technology, such as neuroimaging. 
2 
CHAPTER II 
 
BACKGROUND 
 
Adapted from:   
Thornton-Wells TA, Moore JH, Haines JL.  Genetics, statistics and human disease:  
analytical retooling for complexity.  Trends in Genetics 20: 640-647, 2004. 
 
“If the only tool you have is a hammer, you tend to see every problem as a nail.” 
Abraham Maslow, American psychologist, founder of humanistic psychology 
 
“The difficulty lies, not in the new ideas, but in escaping the old ones.” 
John Maynard Keynes, English economist 
 
Complex Human Genetic Disease 
 Over the past few decades, most of the success in the field of statistical genetics 
has come from identifying genes with substantial main (i.e., independent; non-
interactive) effects on the disease process.  Most statistical tools enabling this success 
were developed for and are primarily effective in the analysis of simple, Mendelian 
diseases such as Huntington disease, cystic fibrosis, and early-onset Alzheimer disease.  
Molecular biologists and geneticists alike now acknowledge that the most common 
human diseases with a genetic component are likely to have very complex etiologies.  
However, despite this belief, statistical geneticists continue using primarily traditional 
3 
methodologies to attack this complex problem.  Traditional statistical methods of genetic 
analysis, such as linkage and association, have failed to consistently replicate findings of 
main effect genes, even though they may explain a majority of the genetic effect of a 
complex disease.  For example, over 115 late-onset Alzheimer disease candidate genes 
have been tested and have generated a positive main effect, but all except apolipoprotein 
E (APOE) have failed to be consistently replicated (Pericak-Vance MA and Haines JL, 
2002).  Among the possible reasons for this failure are false positives due to population 
stratification and true differences in genetic etiology between study populations 
(Hirschhorn JN et al., 2002).  Advances in statistical and computational genetic 
methodology simply have not kept pace with the advance of available sources of data.  
There have been a few attempts to address complexity directly, including the 
development of nonparametric tools, but these have generally limited application.  One 
example is the transmission disequilibrium test that led to the discovery of the insulin 
receptor gene as a risk factor for diabetes (Spielman RS et al., 1993). 
Going forward, statistical geneticists must not only acknowledge but also directly 
confront the numerous complicating factors that can be involved in complex genetic 
diseases and that present significant challenges for traditional statistical methods.  Only a 
small fraction of the human genetics literature specifically reports on investigations of 
such complexity.  It is, perhaps, daunting to consider multiple complicating factors, such 
as locus heterogeneity, trait heterogeneity, and gene-gene interactions (see Figures 1 and 
2).  However, these must be addressed if we are to have any chance of understanding the 
genetic legacy of disease left to us by our forebears. 
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(Rivolta C et al., 2002) 
(Kulczycki LL et al., 2003; Povey S et al., 1994; Young J and Povey S, 1998) 
(Harding AE, 1993; Rosenberg RN, 1995) 
(Devos D et al., 2001) 
(Tager-Flusberg H and Joseph RM, 2003) 
(Bradford Y et al., 2001) 
(Carrasquillo MM et al., 2002) 
(Collinge J et al., 1991; De Silva R et al., 1994; Doh-ura K et al., 1989; Owen F et al., 
1990; Palmer MS et al., 1991) 
 
Fi
gu
re
 1
.  
H
et
er
og
en
ei
ty
-r
el
at
ed
 fa
ct
or
s c
om
pl
ic
at
in
g 
an
al
ys
is
 o
f c
om
pl
ex
 g
en
et
ic
 d
is
ea
se
:  
de
fin
iti
on
s, 
di
ag
ra
m
s a
nd
 
ex
am
pl
es
 
5 
 Fi
gu
re
 1
, c
on
tin
ue
d.
  H
et
er
og
en
ei
ty
-r
el
at
ed
 fa
ct
or
s c
om
pl
ic
at
in
g 
an
al
ys
is
 o
f c
om
pl
ex
 g
en
et
ic
 d
is
ea
se
:  
de
fin
iti
on
s, 
di
ag
ra
m
s a
nd
 e
xa
m
pl
es
 
6 
Fi
gu
re
 2
.  
In
te
ra
ct
io
n-
re
la
te
d 
fa
ct
or
s c
om
pl
ic
at
in
g 
an
al
ys
is
 o
f c
om
pl
ex
 g
en
et
ic
 d
is
ea
se
:  
de
fin
iti
on
s, 
di
ag
ra
m
s a
nd
 
ex
am
pl
es
 
7 
Categorization and Analytical Approaches 
Each of the factors presented in Figures 1 and 2 complicate statistical analysis in 
one of two ways—either by creating heterogeneous, or competing, disease models 
(Figure 1), or else by creating a multifactorial, interacting disease model (Figure 2).  The 
challenge for modeling the relationship between genetic and environmental risk factors 
(independent variables) and disease endpoints (dependent variables) is different for these 
two categories.  Of course, what exacerbates the complexity is that none of these 
competing and interacting models are mutually exclusive.  Various combinations of 
(genetic and/or trait) heterogeneity and interactions might be important in any given 
disease of interest.  Thus, to dissect these factors, we must assemble a toolbox of both 
tried-and-true and newly constructed genetic analysis methodologies, which together can 
be used to discover the true underlying etiologies of complex traits. 
Many complicating factors can be addressed proactively by a well-considered 
study design.  This is perhaps one of the best investments researchers can make to 
maximize their ability to discover complex genetic disease models.  Because the causally 
complex relationship between the genotype and phenotype is the object of genetic 
studies, it is important to collect accurate and abundant phenotypic data.  In the absence 
of phenotypic data, there is not even the option of looking for a mapping between 
genotype and potential clinical subtypes, which could help identify a case of genetic 
heterogeneity.  Established guidelines or protocols concerning data collection should be 
followed and such data should be made available to others in an accessible format, so as 
to facilitate future meta-analysis.  Information regarding the exposure to potential 
environmental risk factors should be collected whenever logistically and economically 
8 
feasible.  Even with the best study design with regard to data collection, an ill-advised or 
incomplete analysis of the data can still yield disappointing, if not incorrect, results.  
Thus, we advocate a comprehensive approach to account for both the heterogeneity and 
the interaction models of disease. 
 
Heterogeneity 
For this category of factors, there are multiple independent (predictor) variables or 
else multiple dependent (outcome) variables that complicate the analysis by creating a 
heterogeneous model landscape.  In the case of allelic or locus heterogeneity or 
phenocopy, multiple predictor variables (e.g. multiple alleles, multiple loci and/or 
environmental risk factors) are present, some of which might be unmeasured or 
unobserved and, therefore, unavailable for inclusion in the disease model.  In the case of 
trait heterogeneity or phenotypic variability, multiple outcome variables are present, 
which cannot or have not been distinguished based on the available phenotypic 
information. 
Perhaps the most straightforward of the methods for addressing heterogeneity is 
sample stratification (Figure 3).  This method subdivides subjects based on any number 
of genetic, demographic, clinical or environmental factors to create more homogeneous 
subsets of the data.  The premise of this method is that there are two or more underlying 
disease models, which are conditional on the factor on which the data are being stratified.  
For example, one genetic model might be associated with disease in the absence of a 
specific environmental risk factor; however, when that environmental factor is present, a 
different set of genetic factors are involved.  Using different levels of the stratifying 
9 
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factor (e.g. different degrees of environmental exposure), one could perform further 
analyses, such as logistic regression (discussed in the following section).  The main 
limitation of sample stratification is a reduction in sample size within each stratum and 
thus a reduction in power. 
Some statistical methods that test the hypothesis of locus heterogeneity include 
the M test (Morton, 1955), the β test (Risch N, 1988) and the Admixture test (Figure 3) 
(Ott, 1992; Smith CAB, 1963).  Each of these methods is solely applicable to family-
based data on which linkage analysis is performed.  The M test uses a priori stratification 
of subjects based on discrete (or discretized) covariates, such as gender, ethnicity or 
clinical subtype, and tests for a difference in recombination fractions across the different 
subsets of families.  The β test is a similar but slightly more powerful statistical test than 
the M test, owing to a difference in their null distributions used to determine statistical 
significance.  The admixture test does not require a priori stratification but instead 
estimates (using maximum likelihood) the degree of admixture present in the sample 
from two-point or multi-point lod scores between marker and disease loci.  It then uses 
these estimates to evaluate the relative probabilities of linkage with and without 
heterogeneity.  Thus, the M and β tests evaluate a more specific hypothesis, and as a 
result, have more power than the admixture test.  The admixture test also lacks sensitivity 
and can only account for, not resolve, the underlying heterogeneity. 
A more recently developed method to address heterogeneity is the ordered subset 
analysis (OSA; Figure 3) (Hauser et al., 1998; Hauser et al., 2004).  In OSA, a continuous 
or ordinal covariate, such as blood lipid levels or disease age of onset, is used to rank 
order families, and then a cumulative lod score is iteratively calculated after each family 
11 
is added (in order) to the sample until the cumulative lod score begins to decrease.  Thus, 
those families included in the linkage analysis all provide support for linkage, and the 
subset of chosen families is more homogeneous with respect to the covariate and, 
therefore, hopefully, more genetically homogeneous than the whole dataset. 
Other methods aimed at producing more homogeneous subsets of the data include 
cluster analysis, latent class analysis and factor analysis (Figure 3).  Unlike the 
aforementioned statistical tests for heterogeneity that only incorporate linkage analysis, 
the following methods can also be applied to case-control datasets because they are not 
tied to any particular statistical analysis of the subsets.  There are hundreds of different 
cluster analysis methods, which operate based on different heuristics and fitness metrics, 
making them appropriate for particular types of data (continuous versus discrete, low- 
versus high-dimensional, and so on).  They all attempt to produce clusters with high 
intraclass similarity and/or low interclass similarity and have varying degrees of success.  
Cluster analysis has been widely used for analyzing DNA and protein microarray data 
(Slonim DK, 2002) and to find more homogeneous subgroups based on genetic 
background (Mountain JL and Cavalli-Sforza LL, 1997). 
Latent class analysis and factor analysis have a goal similar to cluster analysis but 
instead of directly clustering or classifying data based on known covariates, such as the 
scores of different items on a psychological or physical functioning test, these two 
methods try to derive ‘latent’ or underlying variables, such as summary scores of various 
test items, from relationships among the known covariates.  These latent variables are 
then used to classify or stratify the data.  Latent class analysis has been applied to 
phenotypic data for several diseases, including attention deficit hyperactivity disorder 
12 
(Neuman RJ et al., 1999), Alzheimer’s disease (Neuman RJ et al., 2000), autism (Pickles 
A et al., 1995) and schizophrenia (Sham PC et al., 1996). 
It should be noted that all of the methods discussed previously, with the exception 
of the admixture method, depend on covariate data, whether these be known genetic risk 
factors, demographic data, phenotypic data or endophenotypes.  Not only must such 
information be available but also these covariates must actually be relevant to, or be 
surrogates for, the existing heterogeneity.  If the data are incomplete, the performance of 
many of these methods for dissecting heterogeneity suffers and attempts to correct this 
problem by imputing data can introduce spurious associations.  In the absence of such 
relevant, complete data, we are left with seemingly few options of how to proceed when 
we suspect heterogeneity to have a role. 
To overcome some of these problems it might be advantageous to adapt the same 
basic principles of the aforementioned methods to the more complex data.  For instance, 
although clustering methods have been heavily utilized for microarray data, few studies 
have looked into clustering genotypic data from association-based studies to identify 
multilocus patterns that characterize particular subsets of the data.  Some clustering 
methodologies appropriate for such discrete data include hypergraph clustering (Han EH 
et al., 1997a), Bayesian classification (Hanson R et al., 1991) and fuzzy k-modes 
clustering (Huang Z and Ng MK, 1999). 
 
Interactions 
Gene–gene and gene–environment interactions are two complex genetic factors 
(Figure 2) that create a rugged model landscape for statistical analysis. There is clear and 
13 
convincing evidence that gene–gene interactions, whether synergistic or antagonistic, are 
not only possible but also are probably ubiquitous (Moore JH, 2003; Tong AH et al., 
2004). Similarly, gene–environment interactions are likely to be discovered if properly 
investigated. Thus, it is crucial that complex genetic datasets be properly interrogated for 
possible underlying interactions. 
Analytically it can be difficult to distinguish between heterogeneity and 
interactions.  Many of the methods that address heterogeneity might be equally applicable 
to uncovering interactions.  For instance, the discovery of linkage to a particular locus in 
only one subset of data produced by sample stratification could be indicative of 
heterogeneity, or it could be indicative of an interaction between the locus and the 
covariate used to stratify the data. However, there is also an entirely different set of 
methods that are particularly well suited to discovering interactions (but not 
heterogeneity; Figure 4). 
One traditional approach still widely used today is regression.  In particular, 
logistic regression is used when the outcome variable is discrete, for example, disease 
status (i.e. you either have the disease or you do not) (Figure 4).  Logistic regression 
enables direct modeling of the mathematical relationship of genetic and other risk factors 
to disease status.  However, this ‘workhorse’ suffers from the curse of dimensionality, 
meaning that as the distribution of data across numerous combinations of factors becomes 
sparse, the parameter estimates become unreasonably biased, particularly when the ratio 
of sample size to independent variables is below ten to one (Concato et al., 1993; Moore 
JH and Williams SM, 2002; Peduzzi P et al., 1996).  Thus, when considering a 
combination of loci, one or more of which have low minor allele frequencies, the number 
14 
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of individuals with certain multilocus genotype combinations will be so small (or perhaps 
equal to zero), that one cannot reasonably estimate, or generalize to the population, what 
is the disease risk for that combination of genotypes.  Missing or incomplete data can also 
create or exacerbate the problem of sparse data.  In addition, many standard approaches 
to implementing logistic regression, such as forward stepwise regression, require 
significant main effects to be modeled before including interaction effects between 
factors.  This is a major methodological limitation for situations where each locus has 
relatively small main (non-interactive) effects but more substantial interactive effects 
because none of those interactive effects would ever be considered. 
A more recently developed statistical method for evaluating gene–gene 
interactions is the focused interaction testing framework (FITF) (Millstein et al., 2006).  
This method is applicable to case-control data and uses likelihood ratio tests on 
increasingly greater orders of interaction between genes.  To reduce the number of 
interactions tested, a prescreening step is applied in which a goodness-of-fit chi-square 
statistic is used to detect association among candidate genes in the pooled case-control 
data.  Multiple testing is addressed by controlling false discover rates.  This method is 
reported to have better power to detect interactions than Multifactor Dimensionality 
Reduction (MDR, discussed below) when the genes involved have recessive, dominant or 
additive effects (Millstein et al., 2006).  However, the reported difference in power may 
be attributable to the particular implementation of MDR, which differs from that 
recommended by MDR’s authors, and to a disconnect between how the methods 
determine the success of an analysis of simulated data. 
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Another recently developed method for gene-gene interactions is the S-sum 
statistic, which is designed to overcome the curse of dimensionality and the multiple-
testing problems by reducing any number of independent variable statistics into one sum 
statistic and then using permutation testing to correct for an experiment-wise Type I error 
rate, which is the probability of concluding that there is an effect when one does not 
actually exist (Hoh J et al., 2001; Ott J and Hoh J, 2003).  ‘Set association’ analysis is the 
authors’ term for the application of the S statistic to SNP marker data from candidate 
genes or regions (Figure 4).  This method selects the ‘best’ set of n number of single 
nucleotide polymorphisms (SNPs), whose Sn statistic is statistically significant, leading to 
the inference that the entire set of SNPs might be interacting in some way to increase 
disease risk, or else that they are all contributing independently to disease risk.  However, 
because the summed statistics are all single-marker statistics, set association analysis 
does not look at any specific (non-additive) interactive effects among markers and would 
be likely to miss nonlinear or antagonistic types of gene–gene interactions.  This method 
has successfully identified a set of seven SNPs, which together were associated with 
restenosis incidence (P < 0.0001) and explained over 11% of the overall variance (Zee 
RY et al., 2002).  In theory the S statistic can be used with any number of test statistics on 
discrete or continuous data, but its applications and limitations are still being evaluated 
(Wille A et al., 2003). 
When the outcome variable is continuous, as is the case for a quantitative trait 
locus (QTL), such as serum prolactin levels, linear regression can be used to model the 
relationship between risk factors and QTL status (Figure 4).  However, linear regression 
faces the same limitations logistic regression does regarding parameter estimation and 
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modeling interactions.  Cheverud and Routman (Cheverud JM and Routman EJ, 1995) 
developed an alternative parameterization of gene–gene interactions based on its effects 
on genetic variance components (additive, dominance and interaction); however, it is 
limited to evaluating only two loci at a time and all possible genotypes must be present in 
the sample. 
Multivariate adaptive regression splines (MARS) (Cook NR et al., 2004; 
Friedman J, 1991) is a generalization of stepwise linear regression that is particularly 
suited for high-dimensional problems in which many independent variables might be 
modeled.  MARS is also similar to classification and regression trees (CART) (Cook NR 
et al., 2004; Morgan JN and Sonquist JA, 1963; Province MA et al., 2001; Shannon WD 
et al., 2001), which iteratively subdivide data to build a hierarchical classification model.  
A Bayesian belief network (BBN) (Good IJ, 1961) is a probabilistic reasoning system 
that builds a topological (but necessarily hierarchical) model of interactions (joint 
probabilities) (Figure 4).  BBN, CART and MARS all suffer from the same problem of 
sequential conditioning that can plague many other regression-based methods, which 
makes it difficult to discover interactions (especially higher-order interactions) among 
predictor variables, depending on the strength of their individual (or lower-order 
interaction) effects.  The binary nature of CART further limits its ability to model any 
additive interaction.  Still, the most troubling limitation that plagues all these methods is 
their inability to model, much less discover, nonlinear interactions. 
Two types of computational methods—data reduction and pattern recognition—
that come from the computer science field offer the potential for uncovering such 
nonlinear interactions, with increased tolerance for missing or incomplete data (Figure 4).  
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Nelson et al. (Nelson MR et al., 2001) developed a combinatorial partitioning method 
(CPM) that utilizes data reduction to investigate gene–gene interactions. CPM has shown 
success in building multilocus models with nonlinear interactions to explain and predict 
variability in plasma triglyceride (Nelson MR et al., 2001) and plasma plasminogen 
activator inhibitor 1 levels (Moore JH et al., 2002).  Culverhouse et al. (Culverhouse R et 
al., 2004) developed a modification of the CPM method, the restricted partition method 
(RPM), which heuristically restricts the exhaustive search used in CPM and thereby 
reduces its computational load for evaluating interactions.  Multifactor dimensionality 
reduction (MDR) is one data reduction method developed specifically for genotypic data 
that has been successful at finding gene–gene interactions in both simulated data (Hahn 
LW and Moore JH, 2004; Hahn et al., 2003; Ritchie MD et al., 2001; Ritchie MD et al., 
2003) and real data (Ashley-Koch et al., 2006; Cho YM et al., 2004; Ma et al., 2005; Qin 
et al., 2005; Ritchie et al., 2001; Tsai CT et al., 2004; Williams SM et al., 2004).  
Artificial neural networks perform pattern recognition and have been applied to 
genotypic data with varied success (Lucek P et al., 1998; Marinov M and Weeks D, 2001; 
McCulloch W and Pitts W, 1943; Sherriff A and Ott J, 2001).  However, recent work has 
improved the reliability of artificial neural networks through their optimization by 
evolutionary computation (EC) algorithms (Fogel GB and Corne DW, 2002), which use a 
computational search methodology uniquely suited for rugged model landscapes (Ritchie 
et al., 2003b).  One limitation of these computational methods is the potential difficulty 
of interpreting the biological implications of the resulting predictive models (Moore JH 
and Ritchie MD, 2004; Moore and Williams, 2002). 
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Retooling for the Future 
None of the aforementioned methodologies is superior in all respects for the range 
of complicating factors that might be present in any given dataset.  Given the relative 
shortcomings of our current analyses in complex diseases, we need to extend greatly the 
range of available analytical tools.  There is a crucial need for extensive reevaluation of 
existing methodologies for complex diseases, as well as for massive efforts in new 
method development.  It is important that empirical studies be conducted to compare and 
contrast the relative strengths and weaknesses of methods on specific types of problems.  
For example, although cluster analysis has shown promise in numerous other scientific 
and mathematical fields, its use with genetic, particularly discrete genotypic data, has not 
been adequately explored.  Similarly, artificial neural networks modified with 
evolutionary computation have great potential for discovering nonlinear interactions 
among genes and environmental factors.  However, work is still ongoing to evaluate its 
limitations with regard to the heritability and effect sizes that can be detected. 
Ultimately, the real power of existing and yet-to-be-developed methods lies in our 
ability to marry them into a comprehensive approach to genetic analysis, so that their 
relative strengths and weaknesses can be balanced and few alternative hypotheses are left 
uninvestigated.  We propose routinely taking a two-step approach to analysis because no 
single method adequately investigates heterogeneity and interaction issues 
simultaneously.  For example, clustering or ordered subset analysis can be used first to 
uncover genotypic and/or phenotypic heterogeneity and to subdivide the data into more 
homogeneous groups.  Then in a second step, specific tests of interactions, such as the S 
sum statistic approach or the multifactor dimensionality reduction method can be used to 
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investigate gene–gene or gene–environment interactions within each of the homogenized 
subgroups.  This is still not a perfect approach, but it is an important improvement over 
the more common alternative of a single-pronged approach to analysis. 
Such a combined strategy must be the future of genetic statistical analysis.  We 
must harness our knowledge and experience of existing methods even as we open our 
minds to newly fashioned techniques and approaches.  By thus ‘retooling’ our analyses, 
we provide the best opportunity for uncovering the genetic basis of common human 
disease. 
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CHAPTER III 
 
A COMPARISON OF CLUSTERING METHODS 
 
Adapted and expanded from previous work completed for  
Masters Thesis in Biomedical Informatics (2005) and published as follows: 
Thornton-Wells TA, Moore JH, Haines JL.  Dissecting trait heterogeneity: a comparison 
of three clustering methods applied to genotypic data.  BMC Bioinformatics 7:204, 2006. 
 
Background 
 For over 30 years, cluster analysis has been used as a method of data exploration 
(Anderberg MR, 1973).  Clustering is an unsupervised classification methodology, which 
attempts to uncover ‘natural’ clusters or partitions of data.  It involves data encoding and 
choosing a similarity measure, which will be used in determining the relative ‘goodness’ 
of a clustering of data.  No one clustering method has been shown universally effective 
when applied to the wide variety of structures present in multidimensional datasets.  
Instead, the choice of suitable methods is dependent on the type of target data to be 
analyzed.  Clustering has been utilized widely for the analysis of gene expression (e.g., 
DNA microarray) data; however, its application to genotypic data has been limited 
(Slonim DK, 2002). 
Most traditional clustering algorithms use a similarity metric based on distance that 
may be inappropriate for categorical data such as genotypes.  Newer methods have been 
developed with categorical data in mind and include extensions of traditional methods 
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and application of probabilistic theory.  Three such methods were chosen (as discussed in 
a subsequent section) to compare in the task of discovering trait heterogeneity using 
multilocus genotypes—Bayesian Classification (Hanson R et al., 1991), Hypergraph-
Based Clustering (Han EH et al., 1997a), and Fuzzy k-Modes Clustering (Huang Z and 
Ng MK, 1999)—all of which are appropriate for categorical data. 
 
Methods 
 
Data Simulation 
To compare the performance of clustering methodologies in the task of uncovering 
trait heterogeneity in genotypic data, datasets were needed in which such heterogeneity 
was known to exist.  Since there are no well-characterized real datasets available that fit 
this description, a simulation study was needed.  Genetic models that contained two 
binary disease-associated traits, such that there is trait heterogeneity among ‘affected’ 
individuals, were used.  In addition, some of the models incorporate locus heterogeneity, 
a gene-gene interaction, or both.  Figure 5 depicts the structure of the four genetic models 
used to simulate the genotypic data. 
Four prevalence levels were simulated for each genetic model:  (1) fifteen 
percent, which is characteristic of a common disease phenotype such as obesity (Flegal 
KM et al., 1998), (2) five percent, which is characteristic of a relatively common disease 
such as prostate cancer (Narod SA et al., 1995), (3) one percent, which is 
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 Model 1 – Trait Heterogeneity Only 
       
Allelic Variant i of Locus A  DiseaseX-Associated Trait I 
          Disease X 
Allelic Variant ii of Locus B  DiseaseX-Associated Trait II 
 
Model 2 – Trait Heterogeneity with Locus Heterogeneity 
 
Allelic Variant i of Locus A   
     DiseaseX-Associated Trait I  
Allelic Variant ii of Locus B       Disease X 
 
Allelic Variant iii of Locus C  DiseaseX-Associated Trait II 
 
Model 3 – Trait Heterogeneity with Gene-Gene Interaction 
 
Allelic Variant i of Locus A   
     DiseaseX-Associated Trait I  
Allelic Variant ii of Locus B       Disease X 
 
Allelic Variant iii of Locus C  DiseaseX-Associated Trait II 
 
 
Model 4 – Trait Heterogeneity with Locus Heterogeneity and 
Gene-Gene Interaction 
 
Allelic Variant i of Locus A   
     DiseaseX-Associated Trait I  
Allelic Variant ii of Locus B        
          Disease X 
Allelic Variant iii of Locus C   
     DiseaseX-Associated Trait II  
Allelic Variant iv of Locus D 
 
Figure 5.  Structure of Genetic Models Used for Data Simulation 
 
 
characteristic of a less common disease such as schizophrenia (Schultz S and Andreasen 
N, 1999), and (4) one tenth of one percent, which is characteristic of a more uncommon 
disease such as multiple sclerosis (Kurtzke JF, 1991).  Three realistic levels of sample 
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size were simulated for each model:  200, 500 and 1000 affected individuals.  Finally, 
four levels of non-functional loci were simulated:  0, 10, 50 and 100.  The inclusion of 
non-functional loci adds a random noise effect that is present in real candidate gene 
studies in which the functional locus or loci are among many more suspected but actually 
non-functional loci.  All loci, including the functional loci, were simulated to have equal 
biallelic frequencies of 0.5. 
Although the above parameter settings are by no means exhaustive of the 
biologically plausible situations, the outlined conditions are reasonable and specify 192 
different sets of data specifications due to the combinatorial nature of the study design.  
To have adequate power to detect a difference in performance among clustering 
methodologies, 100 datasets per set of parameters were simulated, resulting in a total of 
19,200 simulated datasets. 
 For the purposes of simulating these data, a novel data simulation algorithm 
capable of incorporating these complex genetic factors in an epidemiologically-sound 
manner was designed and developed (Figure 6).  Penetrance is the probability of having a 
particular phenotype given a specific genotype (single or multilocus).  Prevalence, on the 
other hand, is the percentage of individuals in a population that have a particular 
phenotype.  The penetrance levels of the two simulated disease-associated traits are 
constrained by the overall prevalence level of the simulated disease.  The two traits were 
simulated to contribute equally to the prevalence of the associated disease (fifty percent 
trait heterogeneity), such that a small but naturally occurring degree of overlap would be 
present, representing individuals having both disease-associated traits, instead of just one 
or the other.  These penetrance tables are inputs for the new data simulation algorithm. 
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 Penetrance Function Array:  each cell value represents the probability of having the disease-
associated trait, given the (multilocus) genotype 
 
Unaffecteds Probability Array:  each cell value represents the probability of having the multilocus 
genotype given that the disease status is unaffected, which is the probability of being negative 
for all traits, or the joint probability of being negative for each trait, given the genotype 
frequency (prior probability) 
 
Affecteds Probability Array:  each cell value represents the probability of having the multilocus 
genotype given that the disease status is affected, which is the probability of being positive for 
at least one trait, which is the same as 1 – probability of being negative for all traits, or 1- joint 
probability of being negative for each trait, given the genotype frequency (prior probability) 
Pseudocode: 
 
1. Allocate two probability arrays, one for Affecteds and one for Unaffecteds, each of size 
∏∑
= =
L
i
A
j
i
j
1 1
  where L is the total number of loci and Ai is the number of alleles for locus i. 
 
2. For each penetrance function p(Status=Affected | Multilocus Genotype) 
==>Distribute 1-p across relevant cells of Unaffecteds probability array 
 
3. Populate cells of the Affecteds probability array with 1-(cell probability) of corresponding cells of 
the Unaffecteds probability array 
 
4. For each locus  
==>Distribute allele frequencies across appropriate cells of both probability arrays 
 
5. Generate the specified number of unaffected individuals from the Unaffecteds probability array 
 
6. Generate the specified number of affected individuals from the Affecteds probability array 
 
7. Determine the status of each disease-associated trait for each affected individual thus….  If the 
affected individual has a high-risk genotype combination for that disease-associated trait, then 
that individual is affected for that trait.  Otherwise, the individual is unaffected for that disease-
associated trait.  (By design, each affected individual will be affected at one or more disease-
associated traits.) 
Figure 6.  Novel Data Simulation Algorithm.  Simulates trait heterogeneity, locus 
heterogeneity and gene-gene interactions in an epidemiologically-sound manner.  The 
inputs are penetrance function arrays, which are translated into probability arrays for 
affecteds and unaffecteds, separately.  Then affected and unaffected individuals (with 
multilocus genotypes) are simulated from those respective arrays. 
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 For one fourth of the models, trait heterogeneity only is involved (not locus 
heterogeneity or gene-gene interactions), and there is one genetic risk factor for each of 
the two traits.  Each locus acts in a recessive manner, such that affected individuals have 
both copies of the high-risk allele at the disease-associated “functional” locus (Figure 7).  
A naturally occurring degree of overlap between the two traits can result, such that some 
affected individuals have the high-risk genotypes for both traits. 
 
 
(a)  
1A1A 1A1B 1B1B 
0 0 x 
 
(b)  
2A2A 2A2B 2B2B 
0 0 x 
 
Figure 7.  Genetic Model THO (Trait Heterogeneity Only) 
The penetrance tables for Trait I (a) and Trait II (b) are presented.  Cell values indicate 
penetrance level, or the probability of having the trait, given the corresponding multilocus 
genotype.  For each of the two traits, a Mendelian recessive genetic model is used, in 
which the trait is penetrant only when two copies of the high risk (B) allele are present.  
The penetrance (x) is constrained by the desired overall disease prevalence to be 
simulated (0.001, 0.01, 0.05 or 0.15). 
 
 
In the second quarter of the datasets, a locus heterogeneity model described by Li 
and Reich (Li WT and Reich J, 2000) was also simulated (Figure 8b) so that for one of 
the traits, there are two associated loci, each of which is responsible for roughly half of 
the individuals affected with the trait.  In that locus heterogeneity model, each of the 
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functional loci acts in a recessive manner, such that the disease-associated genotype for 
the locus consists of two copies of one high-risk allele.  For the other trait, a recessive 
model was implemented, as described above (Figure 8a). By chance, there might be some 
affected individuals who have the high-risk genotype from the first trait as well as one of 
the high-risk genotypes from the second trait. 
 
 
(a) 
1A1A 1A1B 1B1B
0 0 x 
 
(b) 
  2A2A 2A2B 2B2B
3A3A 0 0 x 
3A3B 0 0 x 
3B3B x x x 
 
 
 
 
 
 
Figure 8.  Genetic Model THL (Trait Heterogeneity with Locus Heterogeneity)   
The penetrance tables for Trait I (a) and Trait II (b) are presented.  Cell values indicate 
penetrance level, or the probability of having the trait, given the corresponding multilocus 
genotype.  For Trait I, a Mendelian recessive genetic model is used, in which the trait is 
penetrant only when two copies of the high risk (B) allele are present.  For Trait II, a 
locus heterogeneity model described by Li and Reich (Li WT and Reich J, 2000) is used, 
in which the trait is penetrant only when two copies of the high risk allele at one or both 
loci are present (in this case the B alleles for locus 2 and 3 are high risk). 
 
 
In the third quarter of the datasets, a gene-gene interaction was simulated for one of 
the two traits.  The “diagonal” gene-gene interaction model, first described by Frankel 
and Schork (Frankel WN and Schork NJ, 1996) and later by Li and Reich (Li WT and 
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Reich J, 2000), which is nonlinear and nonadditive in nature, was used (Figure 9b).  
Under this model, a multilocus genotype is high-risk if it has exactly two high-risk alleles 
from either of the two associated loci.  A multilocus genotype with fewer than or greater 
than two high-risk alleles is not associated with disease.  For the other trait, a recessive 
model was implemented, as described above (Figure 9a).  By chance, there might be 
some affected individuals who have the high-risk genotype from the first trait as well as 
one of the high-risk genotypes from the second trait. 
 
 
(a)  
1A1A 1A1B 1B1B
0 0 x 
 
(b)  
 2A2A 2A2B 2B2B
3A3A 0 0 x 
3A3B 0 0.5x 0 
3B3B x 0 0 
 
Figure 9.  Genetic Model THG (Trait Heterogeneity with Gene-Gene Interaction) 
The penetrance tables for Trait I (a) and Trait II (b) are presented.  Cell values indicate 
penetrance level, or the probability of having the trait, given the corresponding multilocus 
genotype.  For Trait I, a Mendelian recessive genetic model is used, in which the trait is 
penetrant only when two copies of the high risk (B) allele are present.  For Trait II,  the 
“diagonal” genetic model first described by Frankel & Schork (Frankel WN and Schork 
NJ, 1996) and later by Li and Reich (Li WT and Reich J, 2000) is used.  Two loci (2 and 
3) are involved, each with two alleles (A and B), and the trait is penetrant only when 
exactly two copies of the high risk allele from either locus are present. 
 
 
In the fourth quarter of the datasets, one trait is simulated to involve locus 
heterogeneity (Figure 10a), while the other is simulated to involve the “diagonal” gene-
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gene interaction, as described above (Figure 10b).  Thus, there are some affected 
individuals who, by chance, will have one high-risk genotype from the first trait as well 
as one high-risk genotype from the second trait. 
 
 
(a)  
 1A1A 1A1B 1B1B
2A2A 0 0 x 
2A2B 0 0 x 
2B2B x x x 
 
(b)  
 3A3A 3A3A 3A3A
4A4A 0 0 x 
4A4B 0 0.5x 0 
4B4B x 0 0 
 
Figure 10.  Genetic Model THB (Trait Heterogeneity with Both Locus Heterogeneity and 
Gene-Gene Interaction).  The penetrance tables for Trait I (a) and Trait II (b) are 
presented.  Cell values indicate penetrance level, or the probability of having the trait, 
given the corresponding multilocus genotype.  For Trait I, a locus heterogeneity model 
described by Li and Reich (Li WT and Reich J, 2000) is used, in which the trait is 
penetrant only when two copies of the high risk allele at one or both loci are present (in 
this case the B alleles for locus 2 and 3 are high risk).  For Trait II,  the “diagonal” 
genetic model first described by Frankel & Schork (Frankel WN and Schork NJ, 1996) 
and later by Li and Reich (Li WT and Reich J, 2000) is used.  Two loci (2 and 3) are 
involved, each with two alleles (A and B), and the trait is penetrant only when exactly 
two copies of the high risk allele from either locus are present. 
 
 
The input file for each of the clustering methods, which are described below, 
includes genotype and trait status information.  Each row is a single individual.  Column 
headings include unique individual number, trait status (affected for Trait 1, Trait 2, or 
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both), and all simulated loci.  Genotypes for each locus are encoded nominally (not 
ordinally), such that no genetic model assumptions are incorporated.  Loci are numbered, 
and alleles are lettered.  Thus, for a given locus ‘3’ that has two alleles ‘A’ and ‘B’, the 
three possible genotypes are ‘3A3A’, ‘3A3B’, and ‘3B3B’.  A different nomenclature 
could easily be used, however, since the methods simply treat each genotype as a 
character string for labeling purposes only and do not attribute any meaning or order to 
them. 
 
Clustering Methods 
 There exists a very large number of clustering algorithms and even more 
implementations of those algorithms.  The choice of which clustering methodology to use 
should be determined by the kind of data being clustered and the purpose of the 
clustering (Kaufman L and Rousseeuw PJ, 1990).  Genotypic data are categorical, which 
immediately narrows the field of appropriate methods for this study to only a few.  Three 
different clustering methodologies were chosen that are suitable for categorical data and 
are appealing due to their speed or theoretical underpinnings. 
The goal of this cluster analysis is to find a partitioning of the affected individuals 
based on multilocus genotypic combinations that maps onto the trait heterogeneity 
simulated in the data.  For example, consider a dataset with 10 loci (numbered 1 to 10), 
each of which has two alleles (A and B), such that at each locus there are three possible 
genotypes (AA, AB and BB).  It is likely that among affected individuals in the dataset, 
subsets of individuals will share specific genotypes or multilocus combinations of 
genotypes (such as 2B2B; or 3A3B and 9A9B together), either by chance or because such 
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combinations are related to genetic background, phenotypic variability, or trait 
heterogeneity in some way.  Thus, a successful clustering would be one in which all the 
individuals who were simulated to have Trait I end up in one or more clusters that do not 
have any individuals unaffected for Trait I and all individuals who were simulated to 
have Trait II end up in one or more distinct clusters that do not have any individuals 
unaffected for Trait II (Figure 11).  (Those individuals, who by chance have both Trait I 
and Trait II, could be ‘correctly’ placed in any cluster.)  Such a clustering would 
effectively eliminate the noise present among affected individuals due to trait 
heterogeneity.  In the case where locus heterogeneity is also simulated, an even more 
successful clustering would be one in which there are two or more Trait II clusters, each 
of which has only those individuals who have a specific high-risk genotype (e.g., 2B2B 
from Figure 12) and none that do not. 
 
Bayesian Classification 
 The first clustering method is Bayesian Classification (Cheeseman P and Stutz J, 
1996; Hanson R et al., 1991).  The corresponding AutoClass software is freely available 
from Peter Cheeseman at the NASA Ames Research Center.  Bayesian Classification 
(BC) aims to find the most probable clustering of data given the data and the prior 
probabilities.  In the case of genotypic data, prior probabilities are based on genotype 
frequencies, which for the purpose of the proposed data simulations are set in accordance 
with Hardy-Weinberg equilibrium and equal biallelic frequencies of 0.5.  The most 
probable clustering of data is determined from two posterior probabilities.  The first 
involves the probability that a particular individual belongs to its ‘assigned’ cluster, or  
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(a) 
     Locus      Trait  
Indiv 1 2 3 4 5 6 7 8 9 10 1 2 
1 BB AB AB AB AB AA AB BB AB BB X  
2 AB BB BB AB BB BB AB AB BB AB  X 
3 BB BB AA AA AB AB AA AB BB AB X X 
4 AB BB AB AB AB AB BB AB AA AB  X 
5 BB AB AA AB AA AB AA AB AA BB X  
6 BB AB AB AB BB BB AB AA AB AB X  
7 BB BB BB BB AB AB AA AB BB AB X X 
8 AB BB AB AB AA AA AB BB AB BB  X 
9 BB AA AB AB BB AB AB AA AB AB X  
10 AB BB AB BB AB AB BB AB AB AA  X 
11 AA BB AA AA AA AB AA AB AB AB  X 
12 BB AB BB BB AB BB AB BB AA AB X  
13 AB BB AB AA AB AB BB AB AA AA  X 
14 BB AA AB AB BB BB AB AA AB AB X  
15 AB BB BB BB AB AA AB BB AB AA  X 
 
(b) 
     Locus      Trait  
Indiv 1 2 3 4 5 6 7 8 9 10 1 2 
1 BB AB AB AB AB AA AB BB AB BB X  
3 BB BB AA AA AB AB AA AB BB AB X X 
5 BB AB AA AB AA AB AA AB AA BB X  
6 BB AB AB AB BB BB AB AA AB AB X  
9 BB AA AB AB BB AB AB AA AB AB X  
12 BB AB BB BB AB BB AB BB AA AB X  
14 BB AA AB AB BB BB AB AA AB AB X  
 
(c) 
     Locus      Trait  
Indiv 1 2 3 4 5 6 7 8 9 10 1 2 
2 AB BB BB AB BB BB AB AB BB AB  X 
4 AB BB AB AB AB AB BB AB AA AB  X 
7 BB BB BB BB AB AB AA AB BB AB X X 
8 AB BB AB AB AA AA AB BB AB BB  X 
10 AB BB AB BB AB AB BB AB AB AA  X 
11 AA BB AA AA AA AB AA AB AB AB  X 
13 AB BB AB AA AB AB BB AB AA AA  X 
15 AB BB BB BB AB AA AB BB AB AA  X 
 
Figure11.  Hypothetical Clustering of a THO Dataset 
(a) A small dataset consistent with the Trait Heterogeneity Only (THO) genetic model 
(see Figure 7) is presented.  All individuals with the high risk genotype (BB) at locus 1 
have Trait I, and all individuals with the high risk genotype (BB) at locus 2 have Trait II.  
Some individuals have both high risk genotypes and, therefore, both traits. 
A successful clustering of this dataset might be one in which there are two clusters (b) 
and (c), such that one cluster contains only individuals who have Trait I (b) and the other 
cluster contains only individuals who have Trait II (c). 
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otherwise stated as the probability of the individual’s multilocus genotype, conditional on 
it belonging to that cluster, with its characteristic genotypes.  The second posterior 
probability involves the probability of a cluster given its assigned individuals, or 
otherwise stated as the probability of the cluster’s characteristic genotypes, conditional on 
the multilocus genotypes of the individuals assigned to that cluster. 
In actuality, individuals are not ‘assigned’ to clusters in the hard classification 
sense but instead in the fuzzy sense they are temporarily assigned to the cluster to which 
they have the greatest probability of belonging.  Thus, each individual has its own vector 
of probabilities of belonging to each of the clusters.  The assignment of individuals is also 
not considered the most important result of the clustering method.  A ranked listing is 
produced of all loci in the dataset with their corresponding normalized “attribute 
influence” values (ranging between 0 and 1), which provide a rough heuristic measure of 
relative influence of each locus in differentiating the classes from the overall dataset.  
Thus, emphasis is placed on the identification of which attributes, or loci, are most 
important in producing the clustering.  This information that can then be used to more 
directly stratify affected (and/or unaffected) individuals, for instance, by using the top n 
most influential loci identified, and to enable meaningful interpretation of the clustering 
result. 
 
Hypergraph Clustering 
 The second method is Hypergraph Clustering (Han EH et al., 1997a).  It has been 
implemented in the hMETIS software, which is freely available from George Karypis at 
the University of Minnesota.  Hypergraph clustering seeks a partitioning of vertices, such 
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that intracluster relatedness meets a specified threshold, while the weight of hyperedges 
cut by the partitioning is minimized.  In this case, vertices represent single locus 
genotypes, hyperedges represent association rules, and hyperedge weights represent the 
strength of the association rules.  For instance, if a specific genotype at one locus co-
occurs with a specific genotype at another locus, an association rule linking those two 
genotypes would be created, and that rule would have a weight equivalent to the 
proportion of individuals in the dataset that had both of those genotypes.  Thus, for our 
purposes, association rules are multilocus genotype combinations that are found in the 
dataset.  The freely available LPminer program was used to generate the association rules 
(Seno M and Karypis G, 2001).  LPminer searches the database for multilocus genotype 
combinations that appear together with substantial frequency (above a prespecified 
“support” percentage) and outputs this info as a list of association rules.  hMETIS takes 
these association rules and uses them to create a hypergraph in which single locus 
genotypes are vertices and association rules dictate the presence and weight of 
hyperedges.  hMETIS creates a partition of the hypergraph such that the weight of the 
removed hyperedges is minimized.  It achieves this by using a series of phases, somewhat 
analogous to the stages of a simulated annealing algorithm, in an attempt to avoid making 
decisions which are only locally (not globally) optimal. 
This process results in a partitioning (or clustering) of the genotypes in a dataset.  
If a single dataset were being analyzed, this information by itself could be sufficiently 
helpful since it would provide information about which multilocus genotypes appear with 
such frequency that they characterize groups of individuals.  Individuals could be directly 
stratified using such multilocus combinations (similar to the way attribute influence 
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values in the Bayesian Classification method could be used).  However, for the purpose 
of comparing the results of Hypergraph Partitioning to those of the other two methods, 
which produce clusters, or partitions, of individuals (not genotypes), such a partitioning 
of individuals still needed to be created.  Since a given individual could have more than 
one of the multilocus genotypes specified by different hyperedges in the final 
partitioning, the partitioning of individuals was not entirely straightforward.  Thus, a 
heuristic was devised such that each individual would be assigned to the partition, or 
cluster, for which it had the highest percentage of matching genotypes (Figure 12).  More 
specifically, for each cluster, the number of loci represented by one or more genotypes in 
that cluster was determined (Lc).  Then, for each individual, for each cluster, the number 
of matching genotypes between the cluster and the individual (Mic) was divided by Lc, 
producing a vector of similarity percentages per individual, similar to the vector of 
probabilities used by the Bayesian Classification and Fuzzy k-Modes Clustering methods.  
Each individual was then assigned to the cluster with which it had the greatest similarity. 
 
Fuzzy k-Modes Clustering 
The third clustering method is Fuzzy k-Modes Clustering (Huang Z and Ng MK, 
1999).  k-Modes is a trivial extension to categorical data of the popular k-means 
algorithm.  In both methods, cluster centroids can be initialized at random or by one of 
many seeding strategies (Duda RO and Hart PE, 1973), and individuals are assigned to 
their nearest cluster centroids.  Then, cluster centroids are reevaluated based on their 
newly assigned individuals.  For the k-means algorithm, the centroid is calculated as the 
mean vector of genotypes across individuals.  However, for nominal data, such means are  
36 
(a) 
 
Cluster 1 Cluster 2 Cluster 3
1B1B  2B2B  7A7B 
3A3B    9A9A 
 
(b) 
 
     Locus      
 Percentage 
of Matching 
Genotypes 
by Cluster 
 
Indiv 1 2 3 4 5 6 7 8 9 10 1 2 3 
1 BB AB AB AB AB AA AB BB AB BB 100 0 50 
2 AB BB BB AB BB BB AB AB BB AB 0 100 50 
3 BB BB AA AA AB AB AA AB BB AB 50 100 0 
4 AB BB AB AB AB AB BB AB AA AB 50 100 50 
5 BB AB AA AB AA AB AA AB AA BB 50* 0 50 
6 BB AB AB AB BB BB AB AA AB AB 100 0 50 
7 BB BB BB BB AB AB AA AB BB AB 50 100 0 
8 AB BB AB AB AA AA AB BB AB BB 50 100 50 
9 BB AA AB AB BB AB AB AA AB AB 100 0 50 
10 AB BB AB BB AB AB BB AB AB AA 50 100 0 
11 AA BB AA AA AA AB AA AB AB AB 0 100 0 
12 BB AB BB BB AB BB AB BB AA AB 50 0 100** 
13 AB BB AB AA AB AB BB AB AA AA 50 100 0 
14 BB AA AB AB BB BB AB AA AB AB 100 0 50 
15 AB BB BB BB AB AA AB BB AB AA 0 100 50 
 
Figure 12.  Example of Post-processing of Hypergraph Clustering Result 
Hypergraph clustering produces a clustering of genotypes, instead of individuals.  Thus, a 
clustering of individuals must be induced from this clustering of genotypes.  As described 
in the text, an individual in assigned to the cluster for which it has the highest percentage 
of matching genotypes.  Given the dataset presented in Figure 11(a) and a clustering of 
genotypes that is presented here (a), a clustering of individuals can be induced (b). For 
each individual (row), the percentage of matching genotypes that is highlighted indicates 
to which cluster the individual becomes assigned.  Notice that for individual 5, there is a 
tie between the percentage of matching genotypes for clusters 1 and 3.  In such cases, we 
arbitrarily assign the individual to the lower numbered cluster.  Since cluster 3 does not 
contain any high-risk genotypes, it does not facilitate the goal of creating a clustering that 
maps to the simulated trait heterogeneity, and in the case of individual 12, it ends up 
capturing an individual who would preferably be clustered in cluster 1. 
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not necessarily meaningful, and the k-modes algorithm instead determines the centroid as 
the mode vector of genotypes across individuals.  Genotypes are encoded nominally (not 
ordinally), such that no two genotypes are considered ‘closer’ than another two, and the 
‘distance’ between an individual and a centroid is calculated as the cumulative number of 
non-matching genotypes across all loci.  After cluster centroids are reevaluated, 
individuals are again assigned to their nearest centroids, and this process is repeated until 
the assignment of individuals to clusters does not change.  Figure 13 demonstrates the 
first steps of the k-modes clustering, using the same dataset presented in Figures 11 and 
12.  The straightforward algorithm was developed in the C++ language.  The number of 
clusters (k) was prespecified to be 2, 3, 4, 5 or 6.  All five possible k were run for each 
dataset.  Each cluster centroid was initially set to the values of a randomly selected 
individual in the dataset being analyzed.  Both a ‘fuzzy’ and a ‘hard’ version of the k-
modes algorithm were implemented and tested, and while their results on test datasets 
were comparable, the fuzzy version did perform slightly better and provided more 
information, which could be used for interpretation of results.  Thus, the fuzzy version 
was chosen for use in these analyses. 
 
Statistical Analysis 
 
Comparison of Clustering Methods 
Each clustering method has its own metric(s) for evaluating the “goodness” of a 
clustering of data.  Since these methods are being tested on simulated data, classification 
error of a given clustering can be calculated as the number of misclassified individuals  
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(a) 
     Locus      
Cluster 1 2 3 4 5 6 7 8 9 10 
1 (1) BB AB AB AB AB AA AB BB AB BB 
2 (5) BB AB AA AB AA AB AA AB AA BB 
3 (12) BB AB BB BB AB BB AB BB AA AB 
4 (15) AB BB BB BB AB AA AB BB AB AA 
 
(b) 
     Locus      
 Cluster 
Distance 
  
Indiv 1 2 3 4 5 6 7 8 9 10 1 2 3 4 
1 BB AB AB AB AB AA AB BB AB BB 0 6 5 5 
2 AB BB BB AB BB BB AB AB BB AB 8 8 6 6 
3 BB BB AA AA AB AB AA AB BB AB 8 5 7 8 
4 AB BB AB AB AB AB BB AB AA AB 7 6 7 7 
5 BB AB AA AB AA AB AA AB AA BB 6 0 5 10 
6 BB AB AB AB BB BB AB AA AB AB 4 7 5 8 
7 BB BB BB BB AB AB AA AB BB AB 8 6 5 6 
8 AB BB AB AB AA AA AB BB AB BB 4 7 8 4 
9 BB AA AB AB BB AB AB AA AB AB 5 7 8 8 
10 AB BB AB BB AB AB BB AB AB AA 7 8 8 4 
11 AA BB AA AA AA AB AA AB AB AB 9 5 9 8 
12 BB AB BB BB AB BB AB BB AA AB 5 7 0 5 
13 AB BB AB AA AB AB BB AB AA AA 8 7 8 6 
14 BB AA AB AB BB BB AB AA AB AB 5 7 6 8 
15 AB BB BB BB AB AA AB BB AB AA 5 10 5 0 
 
(c) 
     Locus      
Cluster 1 2 3 4 5 6 7 8 9 10 
1  BB AA AB AB BB AA AB AA AB AB 
2  BB BB AA AA AA AB AA AB AA AB 
3  BB BB BB BB AB BB AB AB BB AB 
4 AB BB AB BB AB AB BB AB AB AA 
 
Figure 13.  Example of k-Modes Clustering 
In this example, the same dataset presented in Figure 11 is used to demonstrate the 
different steps involved the k-modes clustering algorithm, and k was chosen to be 4, such 
that four clusters will initially be formed.  (a) The cluster centroids are seeded by 
randomly selecting the genotypes of actual individuals in the dataset.  The number in 
parentheses beside the cluster number is the individual used to seed that cluster.  (b) 
Individuals are then compared to each of the cluster centroids, and the number of 
nonmatching genotypes between each cluster centroid and that individual are recorded.  
The individual is then assigned to the cluster for which it had the fewest number of 
nonmatching genotypes (in bold).  (c) The next step is to update the cluster centroids 
based on the individuals now assigned to the clusters.  The mode genotype among 
individuals assigned to a cluster becomes the centroid genotype at that locus.  Genotypes 
that changed from the initialization to the update are shown in bold. 
39 
(d) 
     Locus      
 Cluster 
Distance 
  
Indiv 1 2 3 4 5 6 7 8 9 10 1 2 3 4 
1 BB AB AB AB AB AA AB BB AB BB 4 9 7 7 
2 AB BB BB AB BB BB AB AB BB AB 6 7 3 7 
3 BB BB AA AA AB AB AA AB BB AB 8 3 4 6 
4 AB BB AB AB AB AB BB AB AA AB 7 6 6 3 
5 BB AB AA AB AA AB AA AB AA BB 8 3 8 8 
6 BB AB AB AB BB BB AB AA AB AB 2 8 6 8 
7 BB BB BB BB AB AB AA AB BB AB 8 4 2 5 
8 AB BB AB AB AA AA AB BB AB BB 5 8 8 6 
9 BB AA AB AB BB AB AB AA AB AB 1 7 7 7 
10 AB BB AB BB AB AB BB AB AB AA 8 7 6 0 
11 AA BB AA AA AA AB AA AB AB AB 8 2 7 6 
12 BB AB BB BB AB BB AB BB AA AB 7 7 3 8 
13 AB BB AB AA AB AB BB AB AA AA 9 5 7 2 
14 BB AA AB AB BB BB AB AA AB AB 1 8 6 8 
15 AB BB BB BB AB AA AB BB AB AA 7 9 5 4 
 
Figure 13, continued.  Example of k-Modes Clustering 
(d) After the centroids are updated, the individuals are reevaluated as to which cluster 
they most closely resemble and are assigned to that cluster.  Only individual 4 was 
assigned to a different cluster than it was previously.  Steps (c) and (d) are repeated until 
no genotypes are changed in any cluster centroid and no individuals’ cluster assignments 
are changed. 
 
 
divided by the total number of individuals.  However, simple classification error has its 
disadvantages.  Firstly, in cases such as this where there is overlap between the known 
classes, the researcher must make an arbitrary decision as to when individuals who have 
been simulated to have both traits, not just one or the other, are considered to be 
misclassified.  The decision about error is equally arbitrary when the number of resulting 
clusters is greater than the number of known classes.  For instance, if the individuals 
belonging to one class were divided into two classes by the clustering algorithm, 
calculating classification error would require either (1) that none of those individuals be 
considered incorrectly classified, since they are all in homogenous clusters, or else (2) 
that all individuals from one of those clusters be considered misclassified.  Neither choice 
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seems to satisfactorily capture the “goodness” of the clustering result.  Subsequently, it is 
not advisable to compare the classification error of two clustering results for which the 
number of clusters differs. 
It is for these reasons alternative cluster recovery metrics were investigated.  The 
Hubert-Arabie Adjusted Rand Index (ARIHA) addresses the concerns raised by 
classification error and was, therefore, chosen to evaluate the goodness of clustering 
results from the three clustering methods being compared (Hubert L and Arabie P, 1985).  
Calculation of the ARIHA involves determining (1) whether pairs of individuals, who 
were simulated to have the same trait, are clustered together or apart and (2) whether 
pairs of individuals, who do not have the same trait, are clustered together or apart.  The 
ARIHA is robust with regard to the number of individuals being clustered, the number of 
resulting clusters, and the relative size of those clusters (Steinley D, 2004).  It is also 
sensitive to the degree of class overlap, which is desirable since it will penalize more for 
good clusterings that occur by chance than classification error would.  When interpreting 
ARIHA values, 0.90 and greater can be considered excellent cluster recovery, 0.80 and 
greater is good cluster recovery, 0.65 and greater reflects moderate cluster recovery, and 
less than 0.65 indicates poor cluster recovery.  These values were derived from empirical 
studies showing observations cut at the 95th, 90th, 85th and 80th percentiles 
corresponded to ARIHA values of 0.86, 0.77, 0.67 and 0.60 respectively (Steinley D, 
2004). 
The ARIHA was used as the gold standard measure to compare the performance of 
the three clustering methods.  Three categorical variables were created that could be 
tested using the nonparametric chi-square test of independence.  The ARIHA values were 
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discretized into a 1 or 0 depending on whether they met or exceeded the cutoff values for 
excellent, good and moderate cluster recovery, as described above.  A chi-square test of 
independence was performed testing the null hypothesis that the number of clusterings 
achieving a certain ARIHA value was independent of the clustering method, thereby 
evaluating whether one method significantly outperformed the others.  Five percent was 
chosen as the significance level (alpha). 
 
Applicability to Real Data 
 As a reminder, the ultimate goal of this research is to find a clustering method that 
works well at uncovering trait heterogeneity in real genotypic data.  Unlike for the 
current simulation study, for real data it is not known a priori to which clusters 
individuals belong, otherwise the clustering would not be necessary.  Indeed, it is the goal 
of clustering to uncover natural clusters or partitions of data using the method-specific 
“goodness” metric as a guide.  In preparation for application of a clustering method to 
real data, after choosing the superior method, that method’s internal clustering metrics 
were analyzed using permutation testing to determine how good a proxy they are for 
ARIHA. 
One hundred permuted datasets per simulated dataset was chosen, which should 
result in a reasonable approximation of the null distribution but would not put 
unreasonable strain on resources and time (Good P, 2000).  Genotypes were permuted 
within loci across individuals, such that the overall frequency of genotypes at any one 
locus was unchanged, but the frequency of multilocus genotypes was altered at random.  
This created a null sample in which the frequency of multilocus genotypes was no longer 
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associated with trait status except by chance.  The empirically-determined superior 
clustering method was applied to each permuted dataset and both the internal clustering 
metric values and the ARIHA were determined.  For each set of 100 permuted datasets, the 
significance of each of the simulated dataset results was determined based on whether 
they exceeded the values at the significance level in the corresponding null distribution.  
Ten percent was chosen as the acceptable Type I error rate since these methods serve as a 
means of data exploration to be followed by more rigorous, supervised analyses on 
individual clusters of the data.  However, the more conventional levels of 0.05 and 0.01 
were also evaluated.  Finally, the ability of permutation testing to preserve acceptable 
Type I (false positive) and Type II (false negative) error rates was evaluated at the three 
specified significance levels. 
 
Results 
 Descriptive statistics and plots for the Hubert-Arabie Adjusted Rand Index results 
were produced.  Mean ARIHA values for Bayesian Classification, Hypergraph Clustering 
and Fuzzy k-Modes Clustering were 0.666, 0.354 and 0.556, respectively.  Confidence 
intervals around the means were also produced to demonstrate the preciseness of the 
ARIHA measurements.  The results for each method across all datasets are presented in 
Table 1.  Mean ARIHA values differed by genetic model type, with higher scores achieved 
on Trait Heterogeneity Only (THO) datasets for the Bayesian Classification and 
Hypergraph Clustering methods (Figure 14). 
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Table 1.  Confidence Intervals around ARIHA Means by Method 
 
   95% Confidence Interval  
Method Mean Standard Error Lower End Upper End 
Bayesian 0.666 0.001 0.664 0.667 
Hypergraph 0.354 0.001 0.352 0.355 
Fuzzy k-Modes 0.556 0.001 0.555 0.558 
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Figure 14.  Comparison of ARIHA Means by Method and Model.  Bars represent means, 
and error bars, which are very short and may be difficult to see, represent 95% 
confidence intervals.  Horizontal lines represent thresholds for quality of cluster recovery:  
0.90 for excellent recovery, 0.80 for good recovery and 0.65 for moderate recovery. 
 
 
Results are displayed as percentages by clustering method (Figure 15) and by 
clustering method and genetic model (Figure 16).  A chi-square test of independence was 
performed testing the null hypothesis that the number of clusterings achieving the 
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specified ARIHA cutoff value was independent of the clustering method.  The three 
methods performed significantly differently on each of the ARIHA cutoff statistics (Table 
2).  Bayesian Classification outperformed the other two methods.  However, across all the 
dataset parameters, Bayesian Classification achieved moderate or better recovery on only 
48% of the datasets (Figure 15). 
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Figure 15.  Percentage of Clustering Results Achieving Cluster Recovery Levels by 
Method 
 
 
 
 
Table 2.  Overall Results of Chi-Square Test of Independence.  The null hypothesis that 
the percentage of clustering results achieving the specified cluster recovery level does not 
differ across clustering methods was tested. 
 
Cluster Recovery Statistic χ2 df p 
%Results achieving Excellent cluster recovery (ARIHA ≥ 0.90) 1787 2 < 0.001
%Results achieving Good cluster recovery (ARIHA ≥ 0.80) 1614 2 < 0.001
%Results achieving Moderate cluster recovery (ARIHA ≥ 0.65) 8565 2 < 0.001
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The performance of the three clustering methods across different dataset parameters 
was evaluated to find particular conditions under which one method consistently 
achieved good or excellent recovery (not just better recovery than the other two 
methods).  For those datasets simulated under the THO model, Bayesian Classification 
performed well, with over 73 percent of its resulting clusterings achieving an ARIHA 
value of 0.90 or greater, indicating excellent recovery (Figure 16).  For this subset of the 
datasets, Bayesian Classification outperformed the other two methods, and again there 
was a significant difference in performance across the three methods, as measured by a 
chi-square test of independence on each of the three new ARIHA cutoff statistics (Table 
3).  Analysis of the other simulation parameters failed to show as great a difference 
among methods where the ‘winning’ method performed as well as the Bayesian 
Classification performed in the THO datasets (data not shown).  Thus, this subset of data 
was chosen for further investigation into the efficacy of using the Bayesian Classification 
method to uncover trait heterogeneity in real data. 
The Bayesian Classification method produces two internal clustering metrics for 
each resulting cluster, or class: (1) class strength, and (2) cross-class entropy.  Class 
strength is a heuristic measure of how strongly each class predicts “its” instances and is 
reported as the log of class strength.  Cross-class entropy is a measure of how strongly 
the class probability distribution function differs from that of the dataset as a whole.  
Because each metric is reported per resulting cluster, or class, the average metric value 
across clusters was calculated and utilized for evaluating cluster fitness.   To evaluate 
the validity of using the Bayesian Classification internal clustering metrics—class 
strength and cross-class entropy—as a proxy for the ARIHA (since ARIHA is unknown for 
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Figure 16.  Percentage of Clustering Results Achieving Cluster Recovery Levels by 
Method and Model 
 
 
 
Table 3.  Results of Chi-Square Test of Independence for THO Datasets. 
The null hypothesis that the percentage of clustering results achieving the specified 
cluster recovery level does not differ across clustering methods was tested. 
 
Cluster Recovery Statistic Model χ2 df p 
%Results achieving Excellent cluster recovery (ARIHA ≥ 0.90) THO 3713 2 < 0.001 
%Results achieving Good cluster recovery (ARIHA ≥ 0.80) THO 3107 2 < 0.001 
%Results achieving Moderate cluster recovery (ARIHA ≥ 0.65) THO 2609 2 < 0.001 
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real data), permutation testing was performed.  Resulting p-values for ARIHA, average log 
of class strength and average cross class entropy were used to calculate false positive and 
false negative rates at three significance levels of 0.01, 0.05 and 0.10.  A clustering result 
was considered a false positive if it was considered significant according to either 
average log of class strength or average cross class entropy but was not considered 
significant according to our ARIHA standard.  A clustering result was considered a false 
negative if it was called not-significant according to both average log of class strength 
and average cross class entropy but was considered significant according to ARIHA.  
Figures 17 and 18 show the false positive and false negative rates, respectively, by alpha 
level. 
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Figure 17.  False Positive Rate by Significance Level (Alpha). 
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Figure 18.  False Negative Rate by Significance Level (Alpha) 
 
 
 The false positive, or Type I, error rate was controlled very well at three percent 
or less for all three significance levels.  The false negative, or Type II, error rate was not 
controlled as well, however.  At the least stringent significance level (α = 0.10), the Type 
II error rate was 18 percent, and at the most stringent level (α = 0.01), the rate was 47 
percent.  Other simulation parameters were examined for their impact on the false 
negative rate, and Figures 19 and 20 show the false negative rate by alpha level paneled 
by number of nonfunctional loci and number of affecteds (sample size), respectively.  As 
might be expected, the lowest false negative rates were achieved for datasets with the 
lowest number of nonfunctional loci (10) and the greatest sample size (1000). 
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Figure 19.  False Negative Rate by Significance Level (Alpha), Paneled by Number of 
Nonfunctional Loci.  These rates are across all genetic models (THO, THL, THG and 
THB). 
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Figure 20.  False Negative Rate by Significance Level (Alpha), Paneled by Number of 
Affecteds (Sample Size).  These rates are across all genetic models (THO, THL, THG 
and THB) 
 
 
51 
Discussion 
 
Data Simulation 
The new data simulation algorithm produced complex genotypic datasets that 
included trait heterogeneity, locus heterogeneity and gene-gene interactions.  Most 
existing simulation software that attempt to simulate heterogeneity do so by allowing the 
user to specify what portion of the dataset is to be simulated under one model versus 
another, and the resulting individuals are simply combined into one dataset.  In the new 
algorithm, however, the disease penetrance models, which were used to simulate the data, 
were constructed so that overall prevalence levels were controlled, allowing naturally 
occurring overlaps, in which some individuals would have both traits (and their 
associated multilocus genotypes) by chance.  This is important because it more closely 
simulates the natural variation one would expect under the “common disease, common 
variant” hypothesis in which there is very little if any selective pressure against alleles 
that increase disease risk only slightly or only in combination with other susceptibility 
alleles at the same or distinct loci (Cargill et al., 1999; Chakravarti, 1999; Reich and 
Lander, 2001; Risch and Merikangas, 1996).  This novel data simulation algorithm 
should prove very useful for future studies of other proposed genetic analysis methods for 
complex diseases. 
 
Comparison of Clustering Methods 
 The Bayesian Classification method outperformed the other two methods across 
most dataset parameter combinations, with the exception of the most complex  
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model (THB) on which Fuzzy k-Modes Clustering performed best.  When the results 
were further examined to find a set of parameters for which one or more methods 
performed well, Bayesian Classification achieved excellent recovery for 73% of the 
datasets with the THO model (Figure 16) and achieved moderate recovery for 56% of 
datasets with 500 or more affecteds and for 86% of datasets with 10 or fewer 
nonfunctional loci (Figures 21 and 22).  Neither Hypergraph Clustering nor Fuzzy k-
Modes Clustering achieved good or excellent cluster recovery even under a restricted set 
of conditions (data not shown). 
Bayesian Classification was obtained as closed-source software, for which there 
are numerous parameters that can be optimized, as discussed in Chapter IV.  Initial 
parameter settings were chosen as recommended by the authors based on the type of data 
being analyzed.  However, it is possible that alternative settings may yield better results.  
For example, for datasets with the more complex genetic models, greater numbers of 
nonfunctional loci and smaller sample sizes, the maximum number of classification trials 
and/or the maximum number of classification cycles per trial may need to be longer, and 
those parameters concerned with convergence rate and stopping criteria may need to be 
changed  to delay convergence.  If improvements in performance could be achieved with 
reasonable time and resource tradeoffs, such changes would certainly be desirable.  
Further investigation of this matter is discussed in Chapter IV. 
It was disappointing that Hypergraph Clustering did not perform very well under 
most conditions, despite its intuitive appeal as a method that would find frequently-
occurring multilocus genotypic patterns.  The Hypergraph Clustering method has been 
reported to work well with very large variable sets (on the order of thousands), which 
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Figure 21.  Percentage of Bayesian Classification Clustering Results Achieving Cluster 
Recovery Levels by Number of Affecteds (Sample Size) 
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Figure 22.  Percentage of Bayesian Classification Clustering Results Achieving Cluster 
Recovery Levels by Number of Nonfunctional Loci 
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have complex patterns for which large numbers of clusters (10-20+) were relevant (Han 
EH et al., 1997b).  However, there has been no examination of the method’s performance 
on smaller variable sets.  Thus, it is possible that the restricted patterns present in our 
multilocus genotypic data were too simple and sparse and that the method is simply tuned 
to search for more complex patterns.  Also, we were required to devise a translation of 
the resulting partitioning of genotypes into a clustering of individuals.  We tested several 
such translations and implemented the best process out of several tested.  Oftentimes, 
even when the method correctly chose the functional genotypes to be in different 
partitions, too many other nonfunctional genotypes were also chosen, which meant that 
the difference between an individual’s likelihood of belonging to one cluster versus 
another was too small, making the choice of cluster assignment almost arbitrary. 
The Fuzzy k-Modes Clustering method performed comparably to Bayesian 
Classification for the more complex datasets and was much less computationally 
intensive.  It has been widely reported that the performance of k-means algorithms is 
highly variable depending on the method of seeding the initial cluster centroids (Duda 
RO and Hart PE, 1973).  While we used the recommended method of selecting 
individuals from the dataset to serve as the initial cluster modes, we perhaps could have 
achieved better results if we implemented an additional step to ensure that the initial 
centroids were substantially dissimilar to each other.  This is supported by evidence that 
when the Fuzzy k-Modes Clustering resulted in only one cluster (effectively no 
partitioning of the data), the initial centroids were very similar and the method had 
converged early so that individuals had equal probability of belonging to any of the 
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clusters.  In such cases, the individual was arbitrarily assigned to the first cluster, thereby 
leading to all other clusters being empty. 
As expected, the simpler the model, the better the performance of the three 
clustering algorithms, with the exception that the Hypergraph Clustering and Fuzzy k-
Modes Clustering methods performed somewhat better on the THB (Trait Heterogeneity 
with Both locus heterogeneity and gene-gene interaction) datasets than they did on the 
THL (Trait Heterogeneity with Locus heterogeneity) and THG (Trait Heterogeneity with 
Gene-gene interaction) datasets.  Likewise, in general, the fewer the nonfunctional loci 
and the larger the sample size, the better the performance. 
 
Applicability to Real Data 
 To determine the efficacy of using the Bayesian Classification method on real 
data, the reliability of its internal clustering metrics at finding good clusterings was 
evaluated.  Using the combination of the average log of class strength and the average 
cross class entropy to determine significance, the false positive rate was controlled very 
well, at three percent or less for all three significance levels.  The false negative rate was 
acceptably low (18 percent) for the less stringent significance levels of 0.10.  However, it 
was high (47 percent) for the most stringent significance level of 0.01.  Thus, if a 
clustering of data were called significant according to permutation testing using either the 
average log of class strength or the average cross class entropy, one could be quite 
confident that the result were real.  Typically geneticists prefer to accept a higher false 
positive rate to increase power; however, there is indeed a trade-off between these two 
types of error.  Valuable time and resources can be spent on follow-up studies, and it can 
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be very detrimental to pursue leads that do not have a good chance of yielding new 
information about the disease under study.  Therefore, we would recommend the 
Bayesian Classification method for use in the first stage of a comprehensive analysis 
strategy to detect heterogeneity and then main effects and interactions, with the caveat 
that a negative result should be interpreted carefully and may indicate that other methods 
for detecting heterogeneity should be considered as well. 
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CHAPTER IV 
 
FURTHER EVALUATION OF BAYESIAN CLASSIFICATION 
 
Background 
 The Bayesian Classification method is effective at uncovering trait heterogeneity 
in simulated genotypic data while preserving very low false positive rates and reasonably 
low false negative rates.  However, these results were for the simplest of simulated 
genetic models and may not generalize to more complicated models.  This chapter will 
present an extension of the previous work in which the Bayesian Classification method is 
modified to improve its performance under a wider set of simulation conditions.  As 
discussed in Chapter III, it is possible that the parameter settings used in the initial data 
simulation study were not appropriate for the more complex genetic models.  The goal of 
this study is to test different parameter settings to make improvements in performance for 
the more complex models without compromising performance for the simplest ones. 
In addition, false positive and false negative rates will be determined for a wider 
range of simulation conditions.  It is possible that even though the method performance 
decreases for these more complex models, the false positive rate will remain well-
controlled, such that positive results are very trustworthy, in which case the method 
would still be useful.  Conversely, along with decreased performance, an increased false 
positive rate (decrease in power) would prevent reasonable conclusions from being drawn 
about its results and thus render the method’s use inadvisable.  Thus, determining how 
the method behaves under these wider set of conditions will allow us to have more 
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confidence in our inferences about results from application of Bayesian Classification to 
real data. 
 
Methods 
 
Modification of Parameter Settings 
 The Bayesian Classification method software has over 30 different parameter 
settings that can be modified by the user to tweak the method’s application.  Six 
parameters were chosen as being likely to affect method performance on more complex 
data patterns since they affect how and what kind of search is performed in looking for 
the best clustering of the data.  They determine initial search conditions, the type of 
search performed (i.e., what types of stopping criteria are used), and what values those 
stopping criteria impose.  The six chosen parameters include: (1) start_j_list, (2) 
max_n_tries, (3) try_fn_type, (4) halt_range, (5) halt factor, and (6) max_cycles. 
Table 4 shows the settings for each of these six parameters used in the initial 
simulation study and in the current extension to that study. Only one parameter setting 
was modified at a time, so that the effect of that particular setting change could be 
evaluated in comparison to the initial settings.  For each of the new modified parameter 
settings, Bayesian Classification was applied to all 19,200 datasets that were simulated 
according to specifications detailed in Chapter III. 
One decision the search algorithm must make is what the optimal number of 
clusters is for the data.  The start_j_list parameter specifies a list of numbers that are the 
initial quantity of clusters the search algorithm tries when optimizing this value.  This list 
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guides the search but does not restrict the algorithm, since it will also try other values that 
it deems likely to produce more optimal results.  For the problem of detecting 
heterogeneity, we are primarily interested in clustering results where the number of 
classes is ten or less; therefore, the default start_j_list was modified accordingly (see 
Table 4). 
 
 
Table 4.  Bayesian Classification Parameter Settings in Simulation Studies.  Note that 
try_fn_type is listed twice since all three search strategies were tried—
‘converge_search_3’ initially and both ‘converge’ and ‘converge_search_4’ in the current 
simulation study. 
 
Parameter  Initial Setting Modified Setting 
start_j_list 2,3,5,7,10,15,25 10,9,8,7,6,5,4,3,2,1 
max_n_tries 50 100 
try_fn_type converge_search_3 converge 
try_fn_type converge_search_3 converge_search_4 
halt range 0.5 0.75 
halt_factor 0.0001 0.001 
max_cycles 200 500 
 
 
The max_n_tries parameter specifies a limit on the number of times the algorithm 
will produce a clustering of the data.  Thus, the higher the value of this parameter, the 
longer the search will last and, in theory, the better the likelihood that the algorithm will 
find a globally optimal solution.  The max_n_tries parameter was increased from 50 to 
100, thereby doubling the maximum number of attempts at finding the optimal solution.  
Larger values were tested on a few datasets, but the computation time was not feasible, 
given the large volume of simulated datasets to be evaluated.  Ideally, on a real dataset, 
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one would set this parameter to the default of 0, allowing unlimited numbers of tries at 
reaching the optimal solution, within the constraints of other search parameter settings. 
The try_fn_type parameter specifies one of three search strategies (‘converge’, 
‘converge_search_3’ and ‘converge_search_4’) the algorithm may use in searching for an 
optimal solution.  The three strategies use different types of stopping criteria based on 
convergence measures.  The default setting is the ‘converge’ algorithm, which is thought 
to perform better on a wide variety of problems than the other two algorithms (Taylor W 
et al., 2002).  The authors indicate that the two alternative search algorithms may perform 
better on some problems but will perform substantially worse on others.  Since this was 
one of the most critical parameters, we tried both alternative algorithms. 
The halt_range and halt_factor parameters affect the convergence rate and, 
conversely, the number of cycles the search strategy will use.  Increasing these values 
decreases the convergence rate.  Therefore, we increased each of them, in turn.  The 
halt_range parameter was increased from 0.5 to 0.75.  The halt_factor was increased by a 
factor of ten from 0.0001 to 0.001.  Higher values were also tested but were found to be 
cost-prohibitive in run time. 
The max_cycles parameter specifies an upper limit on the number of cycles the 
search will perform while the convergence criteria have not been met.  The default value 
of 200 was increased to 300.  Higher values were tested on a small number of datasets but 
were found to increase computation time beyond reasonable limits, given the large 
volume of datasets being evaluated. 
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Applicability to Real Data 
 Using the best group of parameter settings, as determined by the aforementioned 
simulations, permutation testing to determine false positive and false negative rates was 
performed on datasets under a wider set of data simulation conditions.  Data simulated 
under the Trait Heterogeneity with Locus Heterogeneity (THL) and Trait Heterogeneity 
with Gene-Gene Interaction (THG) models, as described in Chapter III, were evaluated, 
where the prevalence was 15 percent, the number of nonfunctional loci was either 10 or 
100 and the sample size was either 500 or 1000.  In the interest of time and computational 
resources, only the first 50 (out of 100) replicates of each set of conditions were used, and 
for each of the replicates, 500 permutated datasets were created, resulting in 200,000 
datasets that were analyzed. 
 
Results 
Figures 23-25 show how method performance differed with each parameter 
setting modification, as measured by the percentage of clustered datasets achieving 
moderate (Figure 23), good (Figure 24) or excellent (Figure 25) cluster recovery 
according to the Hubert-Arabie Adjusted Rand Index.  There was essentially no 
improvement in method performance for either model for each of the modified parameter 
settings, and in fact, modifications in two parameters (start_j_list and try_fn_type) led to 
decreases in performance.  Thus, we concluded that the initial parameter settings were the 
best we had discovered and that those settings should be used going forward. 
False positive and false negative rates were calculated based on permutation 
testing results on the THL and THG genetic model datasets, as specified above.  Overall,  
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false positive rates were still well-controlled, although less so for the THG datasets, 
where ten percent of the clustering results determined significant by the Bayesian 
Classification internal clustering metrics (alpha = 0.01) were actually not significant  
according to the Hubert-Arabie Adjusted Rand Index (ARIHA) (Figure 26).  Conversely, 
false negative rates were better for THG datasets than they were for the THL or the 
previously-evaluated THO datasets.  At the most liberal alpha of 0.10, only sixteen 
percent of the clustering results deemed not significant by the internal clustering metrics 
were actually significant by the ARIHA (Figure 26). 
A more detailed breakdown of this same data is presented in Figure 27 showing 
how false positive and false negative rates track with the number of significant results by 
internal clustering metric and by ARIHA, for each set of simulation conditions, where 
alpha is ten percent.  Note that the vast majority of clustering results are significant by 
ARIHA across all sets of conditions and that high error rates are very specific to certain 
sets of simulation conditions.  False positive rates were at or below five percent for all 
sets of simulation conditions.  Even in the worst case, for datasets simulated under the 
more complex THG model, with 10 (versus 100) nonfunctional loci, clusterings results 
still yielded false positive rates between 11 and 12 percent, very close to alpha of ten 
percent.  False negative rates were near zero for most sets of conditions.  However, for 
datasets containing 100 (versus 10) non-functional loci, the false positive rates ranged 
from two to 94 percent, with the highest rates for datasets with 500 (versus 1000) 
affecteds. 
66 
 Figure 26.  Error Rates for THG and THL Genetic Model Results.  False positive rates 
are shown in the first column and false negative results are shown in the second column.  
Row one shows results for the Trait Heterogeneity with Gene-Gene Interaction genetic 
model datasets.  Row two shows results for the Trait Heterogeneity with Locus 
Heterogeneity genetic model datasets.  The three bars represents results at the 
significance levels (alpha) of one percent, five percent and ten percent. 
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Discussion 
 Attempts to improve upon the performance of the Bayesian Classification method 
at the task of detecting heterogeneity in genotypic datasets were unsuccessful.  The 
parameter settings chosen in the initial simulation study detailed in Chapter III, which 
were based on the methods’ authors’ recommendations and the characteristics of the 
simulated data, turned out to be as good as or better than any setting modifications 
applied in the current study. 
 Extended permutation testing of a wider set of simulation conditions provided 
insight into how the method’s two internal clustering metrics—class strength and cross 
class entropy—compare to the gold standard of the Hubert-Arabie Adjusted Rand Index.  
The internal clustering metrics were biased based on the dataset characteristics of sample 
size and, especially, number of non-functional loci.  This is important to keep in mind 
when the Bayesian Classification method is applied to real data, in which the underlying 
pattern of inheritance and presence (or degree) of heterogeneity and gene-gene 
interactions are unknown.  These results suggest that one can place a high degree of 
confidence in a positive (significant) result based on permutation testing of the method’s 
internal clustering metrics, but less so when the number of nonfunctional loci in the 
dataset is fairly low, since a dataset containing a gene-gene interaction may have a 
slightly inflated false positive rate under these conditions. 
Interpretation of a negative (not significant) result is more difficult.  Under the 
majority of conditions simulated, the false negative rate is very well controlled and the 
power to detect the underlying heterogeneity present in the data is high.  However, there 
are large fluctuations in false negative rates due primarily to differences in the number of 
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results considered significant by the internal clustering metrics (Figure 27).  For a dataset 
with a high number of non-functional loci (100) and a moderate sample size (500), the 
false negative rate may approach 100 percent, eliminating all power to detect 
heterogeneity when it exists, which is of course discouraging.  Further simulation studies 
exploring the “breakpoint” or slope of the false negative rates between the two extremes 
of the current simulation conditions may further aid in interpretation of negative results. 
 Even though the current simulation study found that most results were significant 
by permutation testing (using ARIHA), recall that performance as measured by the 
percentage of results achieving ‘excellent’, ‘good’ or ‘moderate’ cluster recovery was 
low (less than 45 percent of datasets achieving moderate cluster recovery) for the more 
complex datasets (Chapter III).  One aspect of this issue is that the internal clustering 
metrics used by Bayesian Classification are biased under certain dataset conditions 
(discussed above).  It is also possible that the null distribution we created, in which the 
relationship within multilocus genotypes was disrupted, was not the most appropriate 
choice for the question we were asking and was, therefore, leading to erroneous 
conclusions.  The goal of the permutation testing is to test whether the clustering results, 
with their corresponding average class strength and average cross-class entropy values, 
have uncovered structure unlikely to be present (by chance) in data that has no real 
(functional) underlying structure.  Perhaps we should permute only the genotypes of the 
known functional loci or of the loci with the highest influence values.  In real data, since 
the functional loci are unknown as such, we would only be able to use influence values as 
a guide to choosing which loci to permute.  This would disrupt the relationship(s) among 
loci already identified by the clustering algorithm as being the strongest, but it would 
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leave any other, presumably weaker multilocus genotype patterns in tact.  Thus, if those 
patterns are sufficiently strong, that the clustering (on the original, unpermuted data) 
would not stand out as being significantly different from what could be found in the 
permuted data.  However, this would shift the bias even more in a conservative direction, 
increasing the false negative rate, which we are interested in reducing. 
 There is also the question of how good we need the clustering results to be.  Is 
moderate cluster recovery (ARIHA >= 0.65) good enough to enable our statistical methods 
to find main effects and/or gene-gene interactions that were previously masked by 
heterogeneity?  Is an ARIHA of only 0.50 or even 0.35 good enough?  To answer that 
question, we would need to perform main effect and gene-gene interaction tests on the 
simulated data before and after clustering and determine the power to detect the effect in 
the before and after datasets.  If a clustering result with a certain ARIHA leads to a 
substantial increase in the power to detect an effect in the data, then the method is 
working well, for our purposes.  If, instead, only a clustering result achieving good 
cluster recovery (ARIHA >= 0.80) aids in the detection of effects obscured by 
heterogeneity, then it is indeed very important that the relationship between ARIHA and 
statistical significance based on permutation testing be well-understood and, if necessary, 
that the permutation testing procedure be modified to enable clearer interpretation of 
results. 
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CHAPTER V 
 
APPLICATION OF TWO-STAGE ANALYSIS APPROACH TO 
LATE-ONSET ALZHEIMER DISEASE DATA 
 
Background 
Alzheimer’s disease (AD; MIM: 104300) is a neurodegenerative disorder 
characterized clinically by a decline in two or more areas of cognition, one of which is 
usually episodic memory, in the absence of acute causes (Pericak-Vance MA and Haines 
JL, 2002).  Presenting symptoms range from memory impairment to visuospatial 
disorientation, language impairment, depression and psychotic episodes.  This range of 
symptoms suggests extensive cortical damage largely in the hippocampus but also in 
posterior-parietal areas, temporal-parietal systems or even frontal lobe areas (Fox NC and 
Rossor MN, 2000; Perry and Hodges, 2000; Roses, 1997; Small et al., 2000).  While 
gross sensory and motor abnormalities generally rule out AD, some moderate 
disturbances similar to those seen with Parkinson Disease (PD), such as tremor, rigidity 
and bradykinesia, may instead suggest a distinct subtype—AD with Parkinson Disease 
(Brown et al., 1998; Chen et al., 1991; Mayeux et al., 1985; Molsa et al., 1984; Perry et 
al., 1997).  While AD can occur as early as the third decade of life (Cruts et al., 1995), it 
most commonly occurs after the sixth decade.  The age of onset for late-onset Alzheimer 
disease (LOAD) is generally defined to be after age 60 or 65 but extends into the ninth 
decade (Pericak-Vance MA and Haines JL, 2002).  The prevalence of AD was estimated 
to be 13.5 million worldwide and 4.5 million in the United States in 2000, with 
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projections for 2005 up to 21.2 million worldwide (Hebert et al., 2003; Katzman R and 
Fox P, 1999).  
AD is defined pathologically by the presence of two abnormalities in the cerebral 
cortex.  The first is senile plaques that have an amyloid beta (Aβ) protein core, and the 
second is neurofibrillary tangles, which contain the microtubule-associated protein tau 
(Goedert M, 1999; Wisniewski et al., 1993).  It remains controversial whether the plaques 
and tangles are themselves pathogenic or whether they are merely “tombstones” of other 
pathogenic processes (Glabe C, 2000).  Only a weak link between plaque load and 
severity of illness has been found, while the load of neurofibrillary tangles may be more 
strongly correlated with severity (Guillozet et al., 2003; Mufson et al., 1999).  Also, both 
plaques and tangles have been found in normal older adults, leading many to suggest that 
these abnormalities are secondary effects arising from the true pathological mechanisms 
underlying AD.  In addition, Lewy bodies, which contain fibrils of aggregated, insoluble 
alpha-synuclein (McKeith et al., 2004), have been observed in up to 20% of AD cases in 
the substantia nigra (which is characteristic of PD) and elsewhere in the brain (Ditter and 
Mirra, 1987; Growden, 1995; McKeith et al., 1996).  A growing body of literature 
suggests substantial overlap among AD, dementia with Lewy bodies, and Parkinson 
Disease (Pericak-Vance MA and Haines JL, 2002).  It is possible that the developments 
of Aβ plaques, neurofibrillary tangles and Lewy bodies have common physiological 
pathways.  However, it is also possible each one of these features (plaques, tangles and 
Lewy bodies) is a distinct trait, with its own etiology, which would mean that AD is a 
heterogeneous trait that would be better defined as the coincident state of having the trait 
for plaques and the trait for tangles.  Likewise, AD with PD could then be better 
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described as the concomitance of the three traits for plaques, tangles and Lewy bodies.  
Such dissection and categorization of AD is speculative and controversial but not without 
support.  
AD has a strong, albeit complex, genetic component, as evidenced by recent 
family-based studies reporting sibling recurrence risk ratios between 4 and 5, indicating 
that a sibling of a person with LOAD is 4-5 times more likely to develop LOAD than 
someone in the general population (Breitner et al., 1988; Hirst et al., 1994; Sadovnick et 
al., 1989).  Also, twin studies show a concordance rate of 0.49 for monozygotic twins 
versus 0.18 for dizygotic twins (Bergem, 1994).  This demonstrates that there is an 
almost 3 fold increased risk of developing AD for siblings that share all, versus (on 
average) half, of their genes with their affected twin.  Still, the fact that the monozygotic 
concordance rate is far from 100 percent suggests that other factors, including 
environment, are likely involved.  In addition, segregation analyses of LOAD show a 
complex genetic etiology with multiple genes and environmental factors involved (Daw 
et al., 1999; Daw et al., 2000; Pericak-Vance MA and Haines JL, 2002; Rao et al., 1994; 
van Duijn et al., 1993).  Some environmental risk factors under investigation include 
head trauma, plasma homocysteine levels and non-steroidal anti-inflammatory drugs, the 
last of which is purported to have a protective effect (Andersen et al., 1995; Breitner et 
al., 1995; Mayeux et al., 1995; Roberts et al., 1994; Seshadri et al., 2002). 
The only known gene conferring risk for LOAD is apolipoprotein E (APOE).  It is 
estimated that at least fifty percent of the genetic effect of LOAD remains unexplained 
(Daw et al., 2000; Roses AD et al., 1995; Slooter et al., 1998).  Over 115 LOAD 
candidate genes have been tested and have generated a positive main effect, but all except 
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APOE have failed to be consistently replicated (Pericak-Vance MA and Haines JL, 2002) 
(Figure 28).  While the initial reports may have been false positive findings, alternatively, 
these inconsistencies could be indicative of heterogeneity and/or environmental 
interactions across the entire phenotype.  Reported differences of incidence and 
prevalence between ethnic and gender groups are also indicative of interactions with 
environment and/or genetic background.  The possibility of gene-gene interactions has 
been explored only superficially (Pericak-Vance MA and Haines JL, 2002).  
Late Onset Alzheimer Disease is just one example of a complex disease, in which 
traditional statistical methods of analysis such as linkage and association have failed to 
identify main effect genes.  Among the possible reasons for this failure are false positives 
due to population stratification and true differences in genetic etiology between study 
populations (Hirschhorn JN et al., 2002).  In addition, while a small number of supervised 
computational methods exist for discovering gene-gene interactions, the power of these 
methods drops dramatically when locus or trait heterogeneity is present (Ritchie et al., 
2003a).  Current statistical approaches for detecting heterogeneity, such as the admixture 
test (Ott J and Hoh J, 2003; Smith, 1963), are neither sensitive nor powerful and can 
merely account for, not resolve, any underlying heterogeneity (see Chapter II). 
It is possible that phenotypic data could be utilized to improve the performance of 
these methods in the face of locus or trait heterogeneity by facilitating heuristic 
stratification of data.  For instance, age of onset data was used to stratify AD patients, 
leading to the detection of association with the apolipoprotein E4 allele in late-onset and 
sporadic cases (Saunders et al., 1993; Strittmatter et al., 1993).  However, for most 
diseases, particularly neurological diseases, little detailed phenotypic data has been  
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consistently collected in combination with genotypic data.  Postmortem histological data 
are rare for cases, even rarer for controls, and neuroimaging can be expensive and 
challenging with mentally ill patients.  It is for these reasons that an unsupervised 
method, such as the Bayesian Classification method investigated in Chapters III and IV, 
which does not rely on phenotypic data, would be valuable to mine potentially 
heterogeneous genotypic data as a means of data stratification and hypothesis generation. 
In Chapter II, a comprehensive two-step approach to analysis was proposed in 
which heterogeneity is first addressed and then main effects and interactions are 
subsequently investigated in the more homogeneous subsets discovered in the first stage.  
In this chapter, an application of this two-stage approach to a LOAD dataset is presented 
in which cluster analysis is first used to uncover heterogeneity and to subdivide the data 
into more homogeneous groups.  Then in the second stage, traditional linkage and 
association tests are used to detect main effects and a computational data reduction 
method is used to investigate gene–gene interactions within each of the subgroups. 
 
Methods 
 
Specifics of Late-Onset Alzheimer Disease Dataset 
The late-onset Alzheimer Disease dataset includes samples obtained by (1) Dr. 
Jonathan L. Haines at Vanderbilt University, Dr. Pericak-Vance at Duke University and 
Dr. Gary Small at UCLA of the Collaborative Alzheimer Project (the CAP dataset), (2) 
the Indiana Alzheimer Disease Center National Cell Repository (the IU dataset), and (3) 
the National Institute of Mental Health Alzheimer Disease Genetics Initiative dataset (the 
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NIMH dataset).  Although the NIMH and IU datasets represent a rich resource for 
generating hypotheses, they are in use by multiple groups (including CAP).  In contrast, 
the CAP dataset represents an independent set of families that can, therefore, be used to 
confirm and extend initial findings. 
All subjects are Caucasian Americans.  Written consent was obtained from all 
participants in agreement with protocols approved by the institutional review board at 
each contributing institution.  Alzheimer Disease was diagnosed according to the 
NINCDS-ADRDA criteria (McKhann et al., 1984).  Age of onset was recorded as the age 
at which the first symptoms were noted by the participant or family member.  Only 
subjects with an age of onset of 65 or greater were included in this late-onset dataset. 
Markers previously genotyped in over 25 candidate genes and a region of interest 
(ROI) on chromosome 10 were included in the dataset.  The data were then ‘cleaned’ to 
remove markers and subjects with high percentages of missing data.  This was an 
iterative process that resulted in a dataset with 148 markers in the chromosome 10 ROI 
and in 22 candidate genes residing on eight different chromosomes.  All chosen markers 
were genotyped in at least 90 percent of included subjects (Figures 29 and 30), and all 
chosen subjects were genotyped for greater than 85 percent of the included markers 
(Figures 31 and 32). 
Most of the functional candidate genes chosen here are purported to have some 
role in LOAD through their involvement in the processing of amyloid precursor protein 
(APP; MIM: 104760), the secretion of its product, Aβ, and/or the phosphorylation of tau 
or regulation of microtubules within neurons.  Table 5 lists alphabetically the 22 genes  
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Figure 29.  Family-Based Data:  Percentage of Missing Genotypes by Marker 
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Figure 30.  Case-Control Data:  Percentage of Missing Genotypes by Marker 
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Figure 31.  Family-Based Data:  Percentage of Missing Genotypes by Subject 
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Figure 32.  Case-Control Data:  Percentage of Missing Genotypes by Subject 
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genotyped in one or both of the samples, along with their full names and identification 
numbers in the Mendelian Inheritance in Man (MIM) and Entrez Genome databases of 
the National Center for Biotechnology Information (NCBI). 
The family-based dataset, derived from all three ascertainment sources, consists 
of 654 families with 1422 subjects with possible, probable or definite LOAD and 744 
cognitively normal elderly individuals.  Of these families, 328 contain a total of 1279 
discordant sibling pairs (DSPs), in which one sibling is affected with LOAD and the 
other is unaffected.  For this sample, there are 138 markers genotyped in 22 genes on 8 
chromosomes, plus the ROI on chromosome 10.  The CAP dataset also includes a clinic-
based unrelated case-control sample of 451 cases with possible, probable or definite 
LOAD and 699 cognitively normal elderly controls who were either spouses of AD 
patients or subjects recruited from outpatient clinics at the participating institutions.  For 
this case-control sample, there are 93 markers genotyped in 19 genes on eight 
chromosomes.  Across the family-based and case-control samples, there are 82 markers 
in common, covering 18 genes on 8 chromosomes and the ROI on chromosome 10.  
Table 6 lists all markers genotyped, giving their chromosomal location and noting 
whether they are genotyped in the family-based dataset and/or the case-control dataset.  
One marker, labeled ‘1920’, is actually a combination of two adjacent single nucleotide 
polymorphisms—rs2456777 and rs2456778—that could not be distinguished by the 
Taqman probe used for genotyping (Liang X et al., 2006). 
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Table 5.  Genes Covered by Markers Genotyped in One or Both Samples 
Symbol Location Name MIM ID 
Gene 
ID 
A2M 12p13.3-p12.3 Alpha-2-macroglobulin 103950 2 
A2MP 12p13.3-p12.3 Alpha-2-macroglobulin pseudogene - 3 
ACE 17q23.3 Angiotensin 1 converting enzyme (petidyl-dipeptidase A) 106180 1636 
AGT 1q42-q43 angiotensinogen 106150 183 
APOE 19q13.2 Apolipoprotein E 107741 348 
CDC2 10q21.1 Cell division cycle 2 116940 983 
COG2 1q42.2 component of oligomeric Golgi complex 2 606974 22796 
GAPDH 12p13 Glyceraldehydes-3-phosphate dehydrogenase 138400 2597 
GAPDHS 19q13.1 Glyceraldehydes-3-phosphate dehydrogenase, spermatogenic 609169 26330 
IDE 10q23-q25 Insulin degrading enzyme 146680 3416 
LIPC 15q21-q23 Lipase, hepatic 151670 3990 
LRP1 12q13-q14 Low-density lipoprotein receptor-related protein 1 107770 4035 
LRRTM3 10q21.3 Leucine-rich repeat transmembrane neuronal 3 protein - 347731 
LTA 6p21.3 Lymphotoxin alpha (TNF superfamily, member 1) 153440 4049 
OLR1 12p13.2-p12.3 
Oxidized density lipoprotein (lectin-
like) receptor 1 602601 4973 
PLAU 10q24 Urokinase-type plasminogen activator 191840 5328 
PPM1H 12q14.1-q14.2 
Protein phosphotase 1H (PP2C domain 
containing) - 57460 
PZP 12p13-p12.2 Pregnancy-zone protein 176420 5858 
TNF 6p21.3 Tumor necrosis factor (TNF superfamily, member 2) 191160 7124 
TNFRSF6 / 
FAS 10q24.1 
Necrosis factor receptor superfamily 
member 6 134637 355 
UBQLN1 9q21.2-q21.3 Ubiquilin 1 605046 29979 
VR22 / 
CTNNA3 10q22.2 
Catenin (cadherin-associated protein), 
alpha 3 607667 29119 
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Table 6.  Markers Genotyped in Family-Based and Case-Control Samples.  Chromosomal 
location is given according to NCBI dbSNP Human Build 126.  Markers with no gene 
listed were chosen to cover the region of interest on chromosome 10. 
 
Chrom Gene Marker NCBI Location Present in Fam Present in CC
1 COG2 rs3789662 227135608 X X
1 AGT rs7536290 227143437 X X
1 AGT rs3789670 227150449 X X
1 AGT rs2478545 227150856 X X
1 AGT rs4762 227152712 X X
1 AGT rs2148582 227156534 X X
1 AGT rs5051 227156607 X X
1 AGT rs1326886 227166495 X X
6 LTA rs1799724 31650461 X X
6 TNF rs1800750 31650942 X X
6 LTA rs1800629 31651010 X X
6 LTA rs361525 31651080 X X
6 TNF rs4645843 31652541 X X
9 UBQLN1 rs7866234 83508371 X
9 UBQLN1 rs2781003 83508569 X X
9 UBQLN1 rs2781002 83508579 X
9 UBQLN1 rs12344615 83510749 X
9 UBQLN1 rs2780995 83520722 X
9 UBQLN1 rs10868038 83521233 X X
9 UBQLN1 rs11140213 83531038 X X
10 rs10826594 29623140 X
10 rs1023207 32134896 X
10 rs1319013 33583935 X
10 rs1148247 35536952 X
10 rs6482044 37892393 X
10 rs6593491 42585568 X
10 rs1890739 45074179 X
10 rs1806797 48357923 X
10 rs7097397 49695402 X
10 rs14327 51735896 X
10 rs1904018 53523252 X
10 rs4998401 55575412 X
10 rs4935648 57804443 X
10 rs10763551 59943904 X
10 CDC2 1920 61896492 X X
10 CDC2 rs7919724 62165848 X X
10 CDC2 rs2448341 62205963 X X
10 CDC2 rs2448347 62215148 X X
10 rs7090884 63632032 X
10 rs1935 64597829 X
10 rs7089698 65054573 X  
83 
Table 6, continued.  Markers Genotyped in Family-Based and Case-Control Samples. 
 
Chrom Gene Marker NCBI Location Present in Fam Present in CC
10 VR22 4783 67208785 X X
10 VR22 rs1786927 67352267 X X
10 VR22 rs2126750 67507709 X
10 VR22 rs4745886 67530329 X X
10 VR22 rs7911820 67534145 X X
10 VR22 rs7070570 67534610 X
10 VR22 rs7074454 67534965 X
10 VR22 rs10822719 67535076 X X
10 VR22 rs6480140 67538887 X
10 VR22 rs922347 67652964 X X
10 VR22 rs4463744 67778486 X X
10 VR22 rs2441718 67806967 X X
10 VR22 rs2939947 67808364 X X
10 VR22 rs2456737 67825340 X X
10 VR22 rs4746606 68061108 X X
10 VR22 rs7909676 68104803 X X
10 LRRTM3 rs1001016 68347044 X X
10 LRRTM3 rs12769870 68347401 X X
10 LRRTM3 rs1925583 68349950 X X
10 LRRTM3 rs2394314 68350254 X X
10 LRRTM3 rs1925577 68358439 X
10 LRRTM3 rs10762122 68386380 X X
10 LRRTM3 rs942780 68406547 X X
10 LRRTM3 rs1925617 68434823 X X
10 LRRTM3 rs1925622 68439644 X X
10 LRRTM3 rs1925632 68469620 X X
10 LRRTM3 rs1952060 68472940 X X
10 LRRTM3 rs2147886 68488649 X X
10 LRRTM3 rs2251000 68494777 X X
10 LRRTM3 rs2764807 68498938 X X
10 LRRTM3 rs10762136 68513538 X X
10 VR22 rs11593235 68546044 X X
10 VR22 rs10997591 68671884 X X
10 VR22 rs7903421 68951738 X X
10 VR22 rs3096244 69080192 X X
10 rs870801 71599752 X
10 rs1227047 73104105 X
10 PLAU rs1916341 75341168 X X
10 PLAU rs2227564 75343107 X X
10 PLAU rs2227566 75343737 X X
10 PLAU rs2227568 75343885 X X
10 PLAU rs4065 75346470 X X
10 rs1898071 77477033 X
10 rs1439042 80374264 X
10 rs1336439 82822237 X
10 rs11816558 84709583 X
10 rs3750686 87198514 X  
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Table 6, continued.  Markers Genotyped in Family-Based and Case-Control Samples. 
 
Chrom Gene Marker NCBI Location Present in Fam Present in CC
10 TNFRSF6 rs1800682 90739943 X X
10 TNFRSF6 rs1324551 90741496 X X
10 TNFRSF6 rs2031612 90756960 X X
10 TNFRSF6 rs2296600 90760419 X X
10 rs4933194 92501347 X
10 IDE rs2251101 94201284 X X
10 IDE rs1832196 94258314 X X
10 IDE rs7076966 94315491 X X
10 IDE rs4646954 94323807 X X
10 IDE rs3758505 94324758 X X
10 IDE rs7099761 94325779 X X
10 IDE rs1544210 94477781 X X
10 rs701865 95371763 X
10 rs4372378 97234998 X
10 rs2039826 99516658 X
10 rs2255901 101629786 X
10 rs3127242 103303589 X
10 rs7084783 105314160 X
10 rs2058980 107379174 X
10 rs10509859 109803462 X
12 GAPD rs7307229 6513864 X
12 GAPD rs3741916 6514252 X
12 GAPD rs3741918 6514517 X
12 GAPD rs1060621 6514957 X
12 GAPD rs1060620 6514983 X
12 GAPD rs1060619 6515042 X
12 A2M rs1800433 9123618 X
12 A2M rs3832852 9137444 X
12 PZP rs10842971 9194563 X X
12 PZP rs3213831 9208040 X X
12 PZP rs2277413 9209051 X X
12 PZP rs3213832 9212768 X X
12 PZP rs12230214 9238059 X X
12 A2MP rs16918212 9276225 X X
12 A2MP rs34362 9276692 X X
12 A2MP rs17804080 9279277 X X
12 OLR1 rs1050283 10203556 X
12 LRP1 rs1799986 55821533 X
12 LRP1 rs1800127 55825349 X
12 LRP1 rs1800174 55846076 X
12 LRP1 rs1800181 55864555 X
12 LRP1 rs2075699 55871411 X
12 LRP1 rs1800154 55875926 X
12 LRP1 rs1800165 55877493 X
12 LRP1 rs11172124 55881222 X
12 LRP1 rs9669595 55881333 X
12 LRP1 rs7956957 55889082 X  
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Table 6, continued.  Markers Genotyped in Family-Based and Case-Control Samples. 
 
Chrom Gene Marker NCBI Location Present in Fam Present in CC
12 PPM1H rs2029721 61435611 X X
15 LIPC rs6078 56621285 X X
15 LIPC rs6083 56625302 X X
17 ACE rs4291 58907926 X X
17 ACE rs4295 58910030 X
17 ACE rs4311 58914495 X
17 ACE rs4329 58917190 X
17 ACE rs4646994 58919636 X X
17 ACE rs4343 58919763 X X
17 ACE rs4353 58924154 X
17 ACE rs4978 58927493 X
19 GAPDS rs4806173 40716765 X X
19 GAPDS rs12984928 40721692 X
19 APOE rs440446 50101007 X X  
 
 
Statistical Analysis 
A comprehensive, two-stage approach to analysis was performed in which 
heterogeneity was first investigated in the dataset and then main effects and gene-gene 
interactions were investigated among the resulting subsets or clusters of data.  Although 
all of the markers in the dataset had been previously tested for main effects and some 
even for interactions, this testing was performed at different time points over the past 10 
years and, therefore, the samples on which they were tested vary to different degrees 
from the sample being analyzed in the current study.  It is for this reason that a 
preliminary analysis of the complete datasets was performed prior to the two-stage 
analysis, using all the main effect and interaction-detection methods proposed for the 
subsets of data. 
 Analysis of deviations from Hardy-Weinberg equilibrium (HWE) and linkage 
equilibrium were tested using the Haploview program (Barrett et al., 2005) on the 
complete case-control and family-based datasets.  Hardy-Weinberg Equilibrium 
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stipulates the expected ratio of individuals in a population who have each of a marker’s 
possible genotypes, based solely on that marker’s allele frequencies.  Deviations from 
HWE in a sample could be indicative of genotyping error or a violation of one HWE’s 
assumptions—random mating, no selection, no mutation, no migration and infinite or 
large sample size.  Alternatively, it could be evidence for association.  Linkage 
disequilibrium (LD) is the statistically observed (population) phenomenon of two or more 
segments of DNA being observed together more often that would be expected by chance.  
When LD exists between two or more markers, there is essentially one signal or effect 
coming from those markers.  If one or more of the markers in LD exhibit an association 
with disease, it could be any one of those markers (or another variant not genotyped in 
the dataset that is also in LD with one or more of these markers) that is the functionally 
relevant one. 
The Bayesian Classification method (Cheeseman P and Stutz J, 1996; Hanson R 
et al., 1991), previously investigated in simulation studies described in Chapters III and 
IV, was used to detect heterogeneity.  For the family-based and case-control data, 
separately, the affected individuals in the dataset were subjected to cluster analysis, and 
the resulting clustering created subsets, which were more homogeneous than the 
complete dataset.  Each cluster subset was then recombined with the entire group of 
unaffected individuals from the respective dataset for subsequent analysis of main effects 
and interactions. 
For the family-based data, two-point heterogeneity lod score (HLOD) linkage 
analysis using FASTLINK and HOMOG (Ott, 1999) and two methods for detecting main 
effect association—the family-based association test (FBAT) (Horvath et al., 2001) and 
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the pedigree disequilibrium test (PDT) (Martin et al., 2000; Martin et al., 2001)—were 
performed.  Linkage analysis tests whether a marker and a disease locus co-segregate 
within families (according to a specific genetic model), in violation of Mendel’s laws, 
which would suggest that the disease susceptibility allele is at or near the marker in 
question.  Both recessive and dominant disease models are tested, and the maximum 
heterogeneity lod score, which is the highest lod score found for either model under the 
range of full range of possible theta values, is reported.  Tests for allelic association are 
nonparametric and detect deviations in the expected frequency of a marker allele with 
respect to disease status, which would suggest that the disease susceptibility allele is, or is 
in linkage disequilibrium with, the marker in question.  The FBAT for allelic association 
uses data from discordant sibpairs and from nuclear families (decomposing extended 
pedigrees, if present, into nuclear families), whereas the PDT can use data from 
discordant sibpairs, from nuclear families, and from intact extended pedigrees (without 
decomposition and accounting for intrafamilial correlation).  For the case-control data, a 
chi-square test of independence was used to detect main effect associations.  In each case, 
a genotype-based model was tested in which the distribution of cases to controls at each 
of the possible genotypes was compared. 
For both the family-based and the case-control datasets, the multifactor 
dimensionality reduction (MDR) method was used to detect gene-gene interactions (Hahn 
et al., 2003; Ritchie et al., 2001).  MDR is a nonparametric data reduction computational 
method that performs an exhaustive search of the data space, looking for combinations of 
genetic markers and/or environmental factors whose genotypes or levels, when reduced 
to a single risk variable with two levels—high- and low-risk—predict disease status.  
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Using 5-fold cross validation, we measured the average balanced prediction accuracy 
(across the five cross-validation intervals) of every possible combination the best one-, 
two- and three-way MDR models.  Accuracy is a function of the percentage of true 
positives (TP) and true negatives (TN), defined as TP/(TP+FN) (Moore et al., 2006).  
Because each of the datasets tested were unbalanced to some degree—meaning that the 
number of affecteds differed substantially from the number of unaffecteds—the metric 
‘balanced accuracy’ was actually used, along with an adjusted threshold for determining 
risk status.  The adjusted threshold further corrects for the imbalance in the data by 
comparing the ratio of affecteds to unaffecteds with the particular multilocus genotype 
being considered to the ratio in the overall dataset.  For each of the one-locus, two-locus 
and three-locus combinations, the ‘best’ MDR model was chosen as the one with the best 
average balanced prediction accuracy.  All ‘best’ MDR models were evaluated for 
statistical significance using permutation testing with 1000 permutations. 
For each of the ‘best’ two- and three-marker MDR models achieving prediction 
accuracy of 55 percent or greater, the markers in those MDR models were used in logistic 
regression analyses to further characterize the underlying statistical models.  Logistic 
regression can determine the structure of the model, in terms of whether markers are 
influencing or predicting disease status primarily through independent (main) effects or 
through interactions with each other.  One can also obtain odds ratios from logistic 
regression, which are helpful in interpreting these models.  For the case-control data, a 
logistic regression analysis was performed in SPSS, and for the family-based data, a 
multivariate logistic regression method, which controls for intrafamily correlation, was 
89 
implemented in SAS (Martin ER et al., 2005; Siegmund et al., 2000) and applied to all 
discordant sibpairs.  
 
Results 
 
Analysis of Complete Datasets 
 Linkage analysis of the complete family-based dataset detected the known effect 
of APOE (HetLOD = 7.963) and other marginal linkage scores (HetLOD between 1 and 
1.5) for one marker in AGT and four markers in VR22.  The FBAT detected the known 
association of APOE (χ2=86.989, df=2, p<0.001) as well as two substantial effects 
(χ2=13.876, df=1, p<0.001 and χ2=9.085, df=1 p=0.003) and one marginal effect 
(χ2=4.343, df=1, p=0.037) in ACE, and five other marginal effects (χ2>4.2, p<0.05) in 
LRRTM3, PLAU and A2MP.  The PDT detected the known association with APOE 
(χ2=98.388, df=2, p<0.001), two other substantial effects—one in A2M (χ2=6.772, df=1, 
p=0.009) and one in ACE (χ2=7.104, df=1, p=0.008)—and 10 other marginal effects (χ2> 
4.5, p<0.05).  Table 7 presents results from all three tests on all markers showing 
statistically significant effects (p<0.05) according to at least one test.  Analysis using the 
chi-square test of independence on the complete case-control dataset detected the known 
association with APOE (χ2=171.62, df=5, p<0.001) and seven other marginal effects in 
CDC2, VR22, LRRTM3 and GAPDH (χ2>6.2, p<0.05) (Table 8). 
MDR gene-gene interaction analysis was performed on both the complete family-
based and complete case-control datasets.  Since MDR works by comparing the ratio of 
affected to unaffected individuals but does not account for intrafamilial correlations, for  
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Table 7.  Main Effect Analysis Results for Complete Family-Based Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
2-Pt Linkage PDT FBAT
Chrom Gene Marker Max HetLOD Chi-Square p-value ChiSquare p-value
1 AGT rs5051 1.033 0.114 0.736 0.010 0.921
10 VR22 rs7070570 1.366 1.416 0.702 0.248 0.619
10 VR22 rs2441718 1.407 0.312 0.577 1.771 0.183
10 VR22 rs2456737 1.038 1.143 0.285 2.835 0.092
10 VR22 rs7909676 1.068 4.540 0.033 2.682 0.101
10 LRRTM3 rs1925622 0.302 2.849 0.091 4.285 0.038
10 LRRTM3 rs1925632 0.140 2.052 0.152 5.283 0.022
10 LRRTM3 rs2764807 0.097 3.556 0.059 4.462 0.035
10 PLAU rs2227568 0.000 5.170 0.023 3.446 0.063
10 PLAU rs4065 0.000 3.152 0.076 4.987 0.026
10 rs4933194 0.052 4.676 0.031 0.886 0.347
12 A2M rs3832852 0.011 6.772 0.009 1.587 0.208
12 A2MP rs34362 0.047 0.904 0.342 4.673 0.031
12 LRP1 rs1800154 0.000 4.017 0.045 2.145 0.143
12 LRP1 rs9669595 0.003 4.599 0.032 1.939 0.164
12 LRP1 rs7956957 0.000 4.059 0.044 2.343 0.126
17 ACE rs4291 0.000 7.104 0.008 13.876 < 0.001
17 ACE rs4295 0.000 3.23 0.072 9.085 0.003
17 ACE rs4646994 0.000 5.481 0.019 3.056 0.080
17 ACE rs4343 0.000 4.516 0.034 3.689 0.055
17 ACE rs4353 0.000 4.887 0.027 3.405 0.065
17 ACE rs4978 0.000 6.503 0.011 4.343 0.037
19 APOE rs440446 7.963 98.388 < 0.001 86.989 < 0.001  
 
 
Table 8.  Main Effect Analysis Results for Complete Case-Control Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
Pearson's
Chrom Gene Marker ChiSquare p-value
10 CDC2 rs2448347 6.581 0.037
10 VR22 rs1786927 7.035 0.030
10 VR22 rs2441718 8.553 0.014
10 VR22 rs2456737 6.222 0.045
10 LRRTM3 rs942780 7.586 0.023
10 LRRTM3 rs1925617 6.465 0.039
12 GAPD rs1060621 7.188 0.027
19 APOE rs440446 171.62 < 0.001  
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family-based data, only discordant sibpairs (DSPs) are used in the analysis.  Two datasets 
were created—the first with only one randomly chosen DSP per family (designated 
‘1DSP’) and the second with all individuals who are part of one or more DSPs in a family 
(designated ‘AllDSPs’).  MDR detected the main effect of APOE in all three datasets 
(Case-Control, 1DSP and AllDSPs) by choosing APOE as the best one-locus models with 
perfect (5 of 5) cross-validation consistency and by including APOE in the best two- and 
three-locus models as well, all of which were statistically significant (p < 0.05) (Table 9).  
To give MDR the opportunity to detect other effects without interference of the APOE 
effect, we excluded APOE from the datasets  
 
 
Table 9.  MDR Analysis Results for Complete Datasets 
Number 
of Loci
Marker Genes 
(Markers)
Avg Bal 
Prediction 
Accuracy p-value
CV 
Consist
Case-
Control 1 APOE (rs440446) 68.32 < 0.001 5
2 APOE (rs440446)      AGT (rs5051) 67.18 < 0.001 2
3
APOE (rs440446)    
PLAU (rs1916341) 
LRRTM3 (rs10762136)
66.18 < 0.001 2
1DSP 1 APOE (rs440446) 59.52 0.01 5
2 APOE (rs440446)    VR22 (rs7909676) 60.23 < 0.001 3
3
APOE (rs440446)    
OLR1 (rs1050283)   
Chr.10 (rs1916341)
57.27 0.04 1
AllDSPs 1 APOE (rs440446) 62.50 < 0.001 5
2 APOE (rs440446)      AGT (rs7536290) 60.47 < 0.001 2
3
APOE (rs440446)    
OLR1 (rs1050283) 
LRRTM3 (rs12769870)
60.27 < 0.001 3
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and re-ran the analysis.  In these subsequent analyses, none of the best one-, two- or 
three-locus models achieved average balanced prediction accuracies of greater than 53 
percent or cross-validation consistency values of more than 2, and none were statistically 
significant (p > 0.20; see Table 10). 
 
 
Table 10.  MDR Analysis Results for Complete Datasets with APOE Excluded. 
Number 
of Loci Marker Genes (Markers)
Avg Bal 
Prediction 
Accuracy p-value
CV 
Consist
Case-
Control 1 A2MP (rs34362) 48.13 0.93 2
2 VR22 (rs10997591)     LRRTM3 (rs10762136) 50.97 0.47 1
3
UBQLN1 (rs2781002)   
VR22 (rs10997591)      
IDE (rs1544210)
52.37 0.21 2
1DSP 1 VR22 (rs7909676) 48.91 0.86 1
2 OLR1 (rs1050283)    Chr.10 (rs1898071) 48.47 0.90 1
3
OLR1 (rs1050283)   
Chr.10 (rs1898071)    
LRRTM3 (rs10762122)
46.99 0.97 1
AllDSPs 1 Chr.10 (rs6482044) 50.55 0.57 2
2 OLR1 (rs1050283)  LRRTM3 (rs2147886) 48.24 0.95 1
3
 OLR1 (rs1050283)  
Chr.10 (rs1898071)     
AGT (rs5051)
48.97 0.88 1
 
 
 
Detection of Heterogeneity 
 Bayesian Classification was applied to each of the complete case-control and 
family-based datasets.  Only affected individuals are used in the cluster analysis.  The 
family-based dataset produced twelve clusters, and the case-control dataset produced four 
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clusters.  To reduce the number of clusters produced by the family-based dataset and to 
focus on heterogeneity that might be present in both datasets, we took the top 30 markers 
from each dataset with the highest influence values and selected those markers present in 
both datasets (31 markers) (Table 11).  Recall that a marker’s influence value provides a 
rough heuristic measure of relative influence that marker had in differentiating the 
clusters from the overall dataset.  Then, we performed the cluster analysis again using  
 
 
Table 11.  Top 30 Highest-Influence Markers Common to Both Datasets 
Chrom Gene Marker FamInfluValue CCInfluValue
1 AGT rs2148582 0.016 0.161
1 AGT rs5051 0.020 0.178
9 UBQLN1 rs2781003 0.118 0.065
9 UBQLN1 rs10868038 0.116 0.024
9 UBQLN1 rs11140213 0.131 0.042
10 VR22 rs922347 0.019 0.118
10 VR22 rs4463744 0.016 0.115
10 VR22 rs2939947 0.027 0.108
10 LRRTM3 rs1001016 0.009 0.089
10 LRRTM3 rs1925617 0.417 0.359
10 LRRTM3 rs1925622 0.393 0.404
10 LRRTM3 rs1925632 0.799 0.940
10 LRRTM3 rs1952060 0.562 0.521
10 LRRTM3 rs2147886 0.840 1.000
10 LRRTM3 rs2251000 0.818 0.932
10 LRRTM3 rs2764807 0.542 0.615
10 LRRTM3 rs10762136 0.441 0.503
10 VR22 rs11593235 0.307 0.279
10 VR22 rs10997591 0.015 0.294
10 VR22 rs3096244 0.024 0.291
10 TNFRSF6 rs1800682 0.033 0.091
10 TNFRSF6 rs1324551 0.023 0.083
10 IDE rs7076966 0.018 0.073
10 IDE rs4646954 0.016 0.078
10 IDE rs3758505 0.017 0.101
10 IDE rs1544210 0.015 0.078
12 PZP rs3213832 0.023 0.071
15 LIPC rs6083 0.019 0.072
17 ACE rs4291 0.369 0.007
17 ACE rs4646994 0.597 0.015
17 ACE rs4343 0.759 0.080  
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only those 31 markers.  This second analysis produced 15 clusters in the family-based 
dataset and 6 clusters in the case-control dataset.  After again ranking the markers by 
their influence values, it was discovered that the top 5 markers were the same in both 
datasets (Table 12).  Therefore, in one final attempt to produce a clustering that was 
similar across both datasets and produced a more reasonable number of clusters, which 
could be subsequently investigated for main effects and interactions, we performed the 
cluster analysis again using only these top 5 markers.  This third and final round of 
clustering produced 5 clusters in the family-based dataset and 3 clusters in the case-
control dataset (Table 13).  Upon closer inspection, two of the five clusters in the family-
based dataset contained only seven and five affected subjects, respectively, making 
subsequent analysis of those clusters inadvisable due to almost no power to detect an 
effect.  Thus, for all intensive purposes, there were only three resulting clusters for each 
of the datasets. 
Permutation testing was performed to determine whether the final clustering 
based on the top five high-influence markers was statistically significant.  In the family- 
based data, the clustering results produced an average class strength value of -4.34 
(p<0.002) and an average cross-class entropy value of 4.00 (p<0.002).  In the case-
control data, the clustering results produced an average class strength value of -2.71 
(p<0.002) and an average cross-class entropy value of 4.43 (p<0.012).  Thus, for each of 
the datasets, the clustering results were significant at our predetermined alpha of ten 
percent (as suggested by our simulation studies in Chapters III and IV). 
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Table 12.  Top Five Highest-Influence Markers from Second-Round of Cluster Analysis 
Chrom Gene Marker FamInfluValue CCInfluValue
10 LRRTM3 rs1925632 0.938 0.792
10 LRRTM3 rs1952060 0.623 0.944
10 LRRTM3 rs2147886 1.000 1.000
10 LRRTM3 rs2251000 0.940 0.834
10 LRRTM3 rs2764807 0.673 0.890  
 
 
Table 13.  Distribution of Affected Individuals in Final Clustering Results 
 Number   of Affecteds 
Cluster Family-Based Data Case-Control Data 
0 673 215 
1 480 157 
2 257 79 
3 7 - 
4 5 - 
 
 
Since the top 5 markers were all in the same gene (LRRTM3), we investigated 
whether they were in linkage disequilibrium (LD) with each other and thus were 
encoding a single haplotype block.  LD analysis using Haploview indeed showed that the 
five markers and four additional flanking markers were all in high LD with each other, 
and it showed the first four markers to be in a haplotype block (Figures 33 and 34).  
Furthermore, inspection of the multi-locus genotypes at the top 5 markers across the three 
clusters in each dataset showed that one multi-locus genotype was predominant in each of 
the three clusters and that these three multi-locus genotypes were the same across the 
case-control and family-based datasets (Table 14). 
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 Figure 33.  Linkage Disequilibrium Plot of Top 5 High-Influence Markers in Family-
Based Dataset.  The top five markers are:  rs1925632, rs1952060, rs2147886, 2251000, 
and rs2764807.  Numbers in each square represent pair-wise R2 values (e.g., the number 
95 in the second square from the left on the top line of the plot indicates an R2 value of 
0.95 for markers rs1925617 and rs1925622).  The markers in bold are those in a 
haplotype block, as defined by the Haploview software program. 
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 Figure 34.  Linkage Disequilibrium Plot of Top 5 High-Influence Markers in Case-
Control Dataset.  The top five markers are:  rs1925632, rs1952060, rs2147886, 2251000, 
and rs2764807.  Numbers in each square represent pair-wise R2 values (e.g., the number 
92 in the second square from the left on the top line of the plot indicates an R2 value of 
0.92 for markers rs1925617 and rs1925622).  The markers in bold are those in a 
haplotype block, as defined by the Haploview software program. 
 
 
Table 14.  Predominant Genotypes for the Top Five High-Influence Markers by Cluster 
  Cluster  
Marker 0 1 2 
rs1925632 A / C C / C A / A
rs1952060 C / T C / C T / T 
rs2147886 C / T C / C T / T 
rs2251000 A / G A / G A / G
rs2764807 C / T C / C T / T 
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Detection of Main Effects in Subsets of Data 
 For each of the three clusters (0,1,2) in the family-based dataset, linkage analysis 
and association analysis by FBAT and PDT were conducted.  For each of the three 
clusters (0, 1, 2) in the case-control dataset, the chi-square test of independence was 
performed.  Since the three clusters in each dataset correspond exactly, due to their 
definition by the same multilocus genotypes at the top 5 high-influence markers, analysis 
results are presented in the following subsections by cluster number. 
 
Cluster 0 Results 
 Table 15 presents results for cluster 0 for all markers with significant scores on at 
least one of the three statistical tests performed (two-point linkage, FBAT and PDT).  For 
cluster 0, linkage analysis found large HetLOD scores (greater than 10) for all five of the 
top high-influence markers plus three flanking markers in the LRRTM3 gene.  Seven 
additional markers in the VR22 gene, which contains the LRRTM3 gene, produced 
HetLOD scores greater than 3.  APOE produced a HetLOD score of 3.75 (reduced from 
7.963 in the complete family-based dataset).  For cluster 0, the FBAT found very strong 
associations with one marker in UBQLN1 (χ2=6.864, df=1, p=0.009), two markers in 
ACE (χ2=13.494, df=1, p<0.001 and χ2=10.875, df=1, p<0.001) and with the APOE 
marker (χ2=59.407, df=2, p<0.001).  Ten other markers in LTA, VR22, LRP1, ACE and 
the ROI on chromosome 10 showed marginal association (χ2>3.9, p<0.05).  For cluster 0, 
the PDT found very strong association with APOE (χ2=59.407, df=2, p<0.001) and 
marginal association with 15 other markers in VR22, LRP1, ACE and the ROI on 
chromosome 10 (χ2>3.9, p<0.05). 
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Table 15.  Main Effect Analysis Results for Cluster 0 Family-Based Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
2-Pt Linkage PDT FBAT
Chrom Gene Marker Max HetLOD Chi-Square p-value Chi-Square p-value
6 LTA rs1799724 1.0995 0.467 0.494 0.069 0.793
6 LTA rs1800629 0.1523 0.711 0.399 4.175 0.041
9 UBQLN1 rs2781003 0 3.046 0.081 6.864 0.009
10 rs6482044 0.6086 4.898 0.027 4.781 0.029
10 rs1904018 1.7161 1.519 0.218 2.566 0.109
10 rs10763551 1.4194 0.863 0.353 1.42 0.233
10 CDC2 rs7919724 1.1955 0.534 0.465 1.603 0.206
10 CDC2 rs2448341 1.1791 0.249 0.618 2.427 0.119
10 rs7089698 0.1562 4.902 0.027 0.854 0.356
10 VR22 rs1786927 1.4381 0.337 0.561 0.017 0.895
10 VR22 rs2126750 1.9445 0.067 0.796 0.227 0.633
10 VR22 rs4745886 4.7019 0.004 0.948 0.002 0.967
10 VR22 rs7911820 4.0837 0.085 0.771 0.086 0.770
10 VR22 rs7070570 2.5327 0.339 0.953 0.08 0.777
10 VR22 rs7074454 4.9523 0.017 0.897 0.141 0.707
10 VR22 rs6480140 1.125 1.114 0.291 0.536 0.464
10 VR22 rs922347 1.619 2.028 0.154 1.049 0.306
10 VR22 rs4463744 1.7541 0.183 0.669 0.785 0.376
10 VR22 rs2441718 4.0431 2.469 0.116 5.021 0.025
10 VR22 rs2939947 3.9423 0.205 0.651 0 0.987
10 VR22 rs2456737 1.1742 3.462 0.063 5.388 0.020
10 VR22 rs4746606 1.2506 0.183 0.669 0.229 0.633
10 VR22 rs7909676 3.1293 5.431 0.020 4.46 0.035
10 LRRTM3 rs1001016 1.0904 0.502 0.479 0.003 0.959
10 LRRTM3 rs12769870 1.8426 1.24 0.266 0.333 0.564
10 LRRTM3 rs2394314 1.6074 0.454 0.501 0 0.995
10 LRRTM3 rs1925577 2.2237 0.453 0.501 0.027 0.869
10 LRRTM3 rs942780 1.8796 0.794 0.373 1.78 0.182
10 LRRTM3 rs1925617 11.1942 0.329 0.566 0.602 0.438
10 LRRTM3 rs1925622 11.2218 0.111 0.740 0.596 0.440
10 LRRTM3 rs1925632 20.2925 0.113 0.737 0.319 0.572
10 LRRTM3 rs1952060 12.638 2.367 0.124 2.107 0.147
10 LRRTM3 rs2147886 20.147 1.076 0.300 1.293 0.256
10 LRRTM3 rs2251000 20.4094 0.221 0.638 0.447 0.504
10 LRRTM3 rs2764807 13.0929 0.159 0.690 0.557 0.455
10 LRRTM3 rs10762136 10.2544 0.159 0.690 2.013 0.156
10 VR22 rs11593235 4.8028 0.677 0.411 1.978 0.160
10 VR22 rs10997591 2.5524 0.053 0.818 0.007 0.932
10 VR22 rs7903421 0.6966 4.57 0.033 1.064 0.302
10 VR22 rs3096244 2.5206 2.081 0.149 0 0.992
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Table 15, continued.  Main Effect Analysis Results for Cluster 0 Family-Based Dataset.  
Significant results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
2-Pt Linkage PDT FBAT
Chrom Gene Marker Max HetLOD Chi-Square p-value ChiSquare p-value
10 rs870801 1.6058 1.214 0.271 2.132 0.144
10 PLAU rs2227564 1.07 0.134 0.714 0.199 0.655
10 PLAU rs2227566 1.0844 0.027 0.869 0.054 0.816
10 PLAU rs2227568 1.5063 0.6 0.439 0.127 0.721
10 PLAU rs4065 1.0192 0.414 0.520 0.401 0.527
10 rs1439042 1.9356 0.082 0.775 0.638 0.424
10 rs1336439 1.194 1.004 0.316 0.905 0.341
10 IDE rs7076966 1.0434 0.051 0.821 0.102 0.750
10 IDE rs7099761 1.1965 0.509 0.475 1.019 0.313
10 rs225590 0 4.447 0.035 3.471 0.062
12 LRP1 rs1800181 0.0002 5.433 0.020 3.001 0.083
12 LRP1 rs1800154 0.0154 4.306 0.038 2.354 0.125
12 LRP1 rs1800165 0.0141 4.976 0.026 3.077 0.079
12 LRP1 rs9669595 0.0914 5.371 0.021 3.954 0.047
12 LRP1 rs7956957 0 3.918 0.048 2.328 0.127
17 ACE rs4291 0 6.339 0.012 13.494 < 0.001
17 ACE rs4295 0 4.831 0.028 10.875 0.001
17 ACE rs4311 0 2.683 0.102 6.534 0.011
17 ACE rs4646994 0 5.236 0.022 4.38 0.036
17 ACE rs4343 0 4.67 0.031 4.766 0.029
17 ACE rs4978 0 5.657 0.017 5.099 0.024
19 APOE rs440446 3.7521 66.373 < 0.001 59.407 < 0.001  
 
 
 In the case-control dataset, very strong associations were found for the top 5 high-
influence values in LRRTM3 and three flanking markers, plus one marker in IDE and the 
APOE marker (χ2>38, p<0.001).  Four other markers in the PLAU, A2MP and ACE 
genes showed marginal association (χ2>8, p<0.05).  Table 16 presents results chi-square 
results for all markers showing significant association (p < 0.05) for the cluster 0 case-
control dataset. 
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Table 16.  Main Effect Analysis Results for Cluster 0 Case-Control Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
Chrom Gene Marker
Pearson's 
Chi-Square p-value
10 LRRTM3 rs1925617 47.383 < 0.001
10 LRRTM3 rs1925622 45.252 < 0.001
10 LRRTM3 rs1925632 185.361 < 0.001
10 LRRTM3 rs1952060 80.66 < 0.001
10 LRRTM3 rs2147886 197.482 < 0.001
10 LRRTM3 rs2251000 171.91 < 0.001
10 LRRTM3 rs2764807 101.962 < 0.001
10 LRRTM3 rs10762136 105.74 < 0.001
10 VR22 rs11593235 38.462 < 0.001
10 PLAU rs2227568 9.118 0.028
10 IDE rs7099761 10.815 0.013
10 IDE rs1544210 19.355 < 0.001
12 A2MP rs34362 8.182 0.042
17 ACE rs4291 8.414 0.038
19 APOE rs440446 118.292 < 0.001  
 
 
When comparing results across the family-based and case-control datasets for 
cluster 0, thirteen markers were found significant (p < 0.05) by the chi-square test in the 
case-control dataset and by at least one test (linkage, FBAT or PDT) in the family-based 
dataset.  These markers include the top 5 high-influence markers in LRRTM3 and four 
flanking markers, plus one marker each in the PLAU, IDE, ACE and APOE genes—
rs2227568, rs7099761, rs4291 and rs440446, respectively. 
 
Cluster 1 Results 
 In the cluster 1 family-based dataset, linkage analysis showed very high HetLOD 
scores (greater than 5) for all five of the top high-influence markers plus four flanking 
markers in the LRRTM3 gene.  Five additional markers in VR22 produced HetLOD 
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scores greater than 3.  Marginal HetLOD scores (greater than 1) were found in another 31 
markers in VR22, LRRTM3, PLAU, IDE, APOE and the ROI on chromosome 10.  Both 
the FBAT and the PDT found very strong association (χ2>39, p < 0.001) with the top 5 
high-influence markers in LRRTM3 and four flanking markers, plus APOE.  The PDT 
found 13 additional markers in CDC2, VR22, PLAU, IDE, A2M, ACE, GAPDHS and 
the ROI on chromosome 10 that showed marginal association (χ2>3.8, p<0.05).  The 
FBAT found marginal association (χ2>4.3, p<0.05) with four of the same markers PDT 
found (in PLAU, IDE and the ROI on chromosome 10). 
 In the cluster 1 case-control dataset, the chi-square test of independence found 
very strong association (χ2>15, p<0.001) with the top 5 high-influence markers in 
LRRTM3 and six flanking markers, plus one marker in GAPDH and APOE.  In addition, 
22 other markers in AGT, UBQLN1, VR22, CDC2, PLAU, IDE, GAPDH, A2MP, LIPC 
and ACE showed marginal association (χ2>6, p<0.05).  Table 18 presents chi-square 
results for all markers showing significant association (p < 0.05) for the cluster 1 case-
control dataset. 
 When comparing across the family-based and case-control datasets for cluster 1, 
17 markers were found significant (p < 0.05) by the chi-square test in the case-control 
dataset and by at least one test (linkage, FBAT or PDT) in the family-based dataset.  
These markers include the top 5 high-influence markers in LRRTM3 and four flanking 
markers, plus three additional markers in VR22 (rs4463744, rs10997591 and rs3096244), 
three markers in CDC2 (1920, rs2448341 and rs2448347), three markers in PLAU 
(rs1916341, rs2227566 and rs4065), and one marker in IDE (rs1832196) and APOE 
(rs440446).  Worth noting, there are two markers in ACE (rs4353 and rs4978) that were  
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Table 17.  Main Effect Analysis Results for Cluster 1 Family-Based Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
2-Pt Linkage PDT FBAT
Chrom Gene Marker Max HetLOD Chi-Square p-value Chi-Square p-value
10 rs10826594 1.2548 0.714 0.398 0.333 0.564
10 rs1023207 1.0589 0.126 0.722 0.21 0.647
10 rs1319013 0.3697 4.306 0.038 1.345 0.246
10 rs6593491 1.5791 0.035 0.851 1.603 0.205
10 rs4998401 1.9603 0.795 0.373 0.948 0.330
10 rs4935648 2.6603 0.088 0.766 0.098 0.754
10 rs10763551 1.2115 0.124 0.725 0.964 0.326
10 CDC2 1920 2.0918 0.405 0.524 1.4 0.496
10 CDC2 rs2448341 0.4463 4.469 0.035 1.071 0.301
10 CDC2 rs2448347 1.2699 0.540 0.463 0.045 0.833
10 rs7090884 1.6566 0.045 0.831 0.024 0.878
10 rs1935 1.644 0.837 0.360 0.497 0.481
10 rs7089698 1.1446 0.168 0.682 0.053 0.818
10 VR22 rs1786927 0.3379 3.882 0.049 3.799 0.051
10 VR22 rs2126750 1.3995 2.579 0.108 0.73 0.393
10 VR22 rs4745886 1.8666 1.927 0.165 1.13 0.288
10 VR22 rs7911820 0.4904 4.311 0.038 4.311 0.038
10 VR22 rs7070570 3.1473 2.359 0.307 0.682 0.409
10 VR22 rs6480140 0.3839 4.953 0.026 4.953 0.026
10 VR22 rs922347 4.5899 0.129 0.720 0.223 0.637
10 VR22 rs4463744 2.1485 0.220 0.639 0.708 0.400
10 VR22 rs2441718 2.1851 0.841 0.359 1.68 0.195
10 VR22 rs2939947 3.6337 0.008 0.929 0.955 0.329
10 VR22 rs2456737 3.2556 1.485 0.223 1.796 0.180
10 VR22 rs4746606 1.4451 0.116 0.733 0.323 0.570
10 VR22 rs7909676 1.7719 1.735 0.188 1.689 0.194
10 LRRTM3 rs12769870 2.6682 0.333 0.564 0.788 0.375
10 LRRTM3 rs1925583 2.6807 1.189 0.276 0.482 0.488
10 LRRTM3 rs2394314 2.8638 0.919 0.338 0.684 0.408
10 LRRTM3 rs1925577 2.3376 0.113 0.737 0.005 0.944
10 LRRTM3 rs1925617 8.2048 45.075 < 0.001 55.866 < 0.001
10 LRRTM3 rs1925622 9.3456 46.140 < 0.001 57.161 < 0.001
10 LRRTM3 rs1925632 14.638 55.764 < 0.001 70.219 < 0.001
10 LRRTM3 rs1952060 7.8202 54.554 < 0.001 67.365 < 0.001
10 LRRTM3 rs2147886 16.7244 53.720 < 0.001 66.162 < 0.001
10 LRRTM3 rs2251000 15.4586 55.748 < 0.001 68.044 < 0.001
10 LRRTM3 rs2764807 10.721 50.449 < 0.001 58.393 < 0.001
10 LRRTM3 rs10762136 10.2257 46.537 < 0.001 57.414 < 0.001
10 VR22 rs11593235 5.976 39.195 < 0.001 45.584 < 0.001
10 VR22 rs10997591 2.55 1.186 0.276 0.277 0.599
10 VR22 rs3096244 1.4214 0.162 0.688 0.603 0.438  
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Table 17, continued.  Main Effect Analysis Results for Cluster 1 Family-Based Dataset.  
Significant results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
2-Pt Linkage PDT FBAT
Chrom Gene Marker Max HetLOD Chi-Square p-value Chi-Square p-value
10 PLAU rs1916341 1.0987 1.801 0.180 1.598 0.206
10 PLAU rs2227564 1.5754 0.025 0.874 0.373 0.541
10 PLAU rs2227566 1.3058 1.848 0.174 1.982 0.159
10 PLAU rs2227568 0.2907 6.470 0.011 5.032 0.025
10 PLAU rs4065 1.2024 1.594 0.207 3.203 0.074
10 rs1439042 1.5462 0.601 0.438 0.424 0.515
10 rs11816558 1.073 0.000 1.000 0.065 0.798
10 IDE rs2251101 0 7.388 0.007 4.788 0.029
10 IDE rs1832196 0.2703 5.028 0.025 6.31 0.012
10 IDE rs4646954 1.1098 1.817 0.178 2.64 0.104
10 rs4372378 0.4067 5.704 0.017 4.995 0.025
12 A2M rs3832852 0.0837 6.674 0.010 1.357 0.244
17 ACE rs4353 0 4.265 0.039 2.425 0.119
17 ACE rs4978 0 3.991 0.046 2.254 0.133
19 GAPDS rs4806173 0.25 4.464 0.035 3.6 0.058
19 APOE rs440446 2.1577 40.994 < 0.001 43.475 < 0.001  
 
 
significant by the FBAT and PDT in the family-based dataset but are not present in the 
case-control dataset.  In the family-based dataset, these markers are in linkage 
disequilibrium with two other markers (rs4646994 and rs4343) that are were found 
significant by the Pearson chi-square test of independence in the case-control dataset. 
 
Cluster 2 Results 
 In the cluster 2 family-based dataset, linkage analysis produced HetLOD scores 
greater than 3 for the top 5 high-influence markers in LRRTM3 and four flanking 
markers, plus one additional marker in VR22.  Marginal HetLOD scores (greater than 1) 
were found in another 18 markers in AGT, VR22, ACE and the ROI on chromosome 10.   
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Table 18.  Main Effect Analysis Results for Cluster 1 Case-Control Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
Chrom Gene Marker
Pearson's 
Chi-Square p-value
1 AGT rs2148582 11.144 0.004
1 AGT rs5051 12.809 0.002
1 AGT rs1326886 8.652 0.013
9 UBQLN1 rs2781003 6.305 0.043
9 UBQLN1 rs2780995 6.794 0.033
9 UBQLN1 rs12344615 7.624 0.022
9 UBQLN1 rs11140213 8.023 0.018
10 CDC2 1920 11.509 0.021
10 CDC2 rs2448341 6.269 0.044
10 CDC2 rs2448347 7.161 0.028
10 VR22 rs4463744 11.652 0.003
10 LRRTM3 rs1925617 73.726 < 0.001
10 LRRTM3 rs1925622 56.225 < 0.001
10 LRRTM3 rs1925632 225.507 < 0.001
10 LRRTM3 rs1952060 92.221 < 0.001
10 LRRTM3 rs2147886 241.493 < 0.001
10 LRRTM3 rs2251000 226.643 < 0.001
10 LRRTM3 rs2764807 138.128 < 0.001
10 LRRTM3 rs10762136 119.639 < 0.001
10 VR22 rs11593235 39.889 < 0.001
10 VR22 rs10997591 26.598 < 0.001
10 VR22 rs3096244 23.893 < 0.001
10 PLAU rs1916341 6.591 0.037
10 PLAU rs2227566 6.866 0.032
10 PLAU rs4065 7.26 0.027
10 IDE rs1832196 7.803 0.020
10 IDE rs7076966 9.976 0.007
12 GAPD rs7307229 8.618 0.013
12 GAPD rs1060620 15.79 < 0.001
12 GAPD rs1060619 14.489 0.001
12 A2MP rs16918212 6.051 0.049
12 A2MP rs17804080 8.722 0.013
15 LIPC rs6083 8.748 0.013
17 ACE rs4646994 6.004 0.050
17 ACE rs4343 8.903 0.012
19 APOE rs440446 91.857 < 0.001  
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Both the FBAT and the PDT found very strong association (χ2>11, p < 0.001) with the 
top 5 high-influence markers in LRRTM3 and four flanking markers, plus APOE.  The 
FBAT found five additional markers in LTA, LRRTM3, PLAU and ACE that showed 
marginal association (χ2>4, p<0.05).  The PDT found one more LRRTM3-flanking 
marker with a very significant association (χ2=12.255, df=2, p < 0.001) and three other 
markers in CDC2, PLAU and LRP1 that showed marginal association (χ2>4.9, p < 0.05).  
Table 19 presents results for cluster 2 for all markers with significant scores (p<0.05) on 
at least one of the three statistical tests performed (two-pt linkage, FBAT and PDT).   
 In cluster 2 case-control dataset, the chi-square test of independence found very 
strong association (χ2>67, p<0.001) with the top 5 high-influence markers in LRRTM3 
and four flanking markers, plus APOE.  In addition, three other markers in VR22 and 
A2MP showed marginal association (χ2>7, p<0.05).  Table 20 presents chi-square results  
for all markers showing significant association (p < 0.05) for the cluster 2 case-control 
dataset. 
 When comparing across the family-based and case-control datasets for cluster 2, 
10 markers were found significant (p < 0.05) by the chi-square test in the case-control 
dataset and by at least one test (linkage, FBAT or PDT) in the family-based dataset.  
These markers include the top 5 high-influence markers in LRRTM3 and four flanking 
markers, plus APOE. 
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 Table 19.  Main Effect Analysis Results for Cluster 2 Family-Based Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
2-Pt Linkage PDT FBAT
Chrom Gene Marker Max HetLOD Chi-Square p-value Chi-Square p-value
1 AGT rs5051 1.7146 0.155 0.694 0.819 0.365
1 AGT rs2148582 1.7798 0.003 0.953 0.38 0.538
6 LTA rs1800629 0 1.573 0.210 4.594 0.032
10 rs10826594 1.0955 0.268 0.605 0.096 0.757
10 rs1319013 1.3621 1.613 0.204 1.747 0.186
10 rs1148247 1.0737 0.109 0.741 1.053 0.305
10 rs6482044 1.3444 0.822 0.365 0.142 0.706
10 rs6593491 1.1512 0.297 0.586 0.985 0.321
10 rs1890739 2.627 0.261 0.610 0.064 0.800
10 rs14327 1.0027 0.43 0.512 0.852 0.356
10 rs10763551 2.3693 0.166 0.684 0.014 0.905
10 CDC2 rs7919724 0.6497 4.955 0.026 2.602 0.107
10 VR22 rs2126750 1.6167 1.152 0.283 1.716 0.190
10 VR22 rs7074454 1.1114 0.674 0.412 0.557 0.456
10 VR22 rs6480140 1.8565 0.653 0.419 0.01 0.920
10 VR22 rs2441718 3.5833 0.576 0.448 0.041 0.839
10 VR22 rs2939947 1.2757 0.272 0.602 0.573 0.449
10 VR22 rs2456737 1.4679 0.052 0.820 0.17 0.681
10 VR22 rs4746606 1.4457 0.193 0.661 0.081 0.776
10 LRRTM3 rs942780 0.1022 12.255 < 0.001 9.648 0.002
10 LRRTM3 rs1925617 3.7431 11.904 0.001 19.368 < 0.001
10 LRRTM3 rs1925622 3.9166 11.062 0.001 18.319 < 0.001
10 LRRTM3 rs1925632 8.2935 23.69 < 0.001 27.201 < 0.001
10 LRRTM3 rs1952060 6.8637 21.041 < 0.001 22.93 < 0.001
10 LRRTM3 rs2147886 9.664 28.35 < 0.001 33.476 < 0.001
10 LRRTM3 rs2251000 9.1483 26.098 < 0.001 33.166 < 0.001
10 LRRTM3 rs2764807 8.4098 21.525 < 0.001 29.282 < 0.001
10 LRRTM3 rs10762136 8.3662 21.407 < 0.001 31.142 < 0.001
10 VR22 rs11593235 6.5029 19.458 < 0.001 20.156 < 0.001
10 PLAU rs2227568 1 7.042 0.008 7.36 0.007
10 rs4933194 1.0466 0.428 0.513 0.039 0.843
12 LRP1 rs1800154 0 5.141 0.023 2.807 0.094
17 ACE rs4291 0.001 1.373 0.241 4.729 0.030
17 ACE rs4343 0.0855 2.33 0.127 4.077 0.043
19 APOE rs440446 0.5671 36.984 < 0.001 25.785 < 0.001  
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Table 20.  Main Effect Analysis Results for Cluster 2 Case-Control Dataset.  Significant 
results are highlighted in pale (p<0.05) or fluorescent (p<0.01) yellow. 
 
Chrom Gene Marker
Pearson's 
Chi-Square p-value
10 LRRTM3 rs1925617 96.408 < 0.001
10 LRRTM3 rs1925622 93.924 < 0.001
10 LRRTM3 rs1925632 182.472 < 0.001
10 LRRTM3 rs1952060 134.996 < 0.001
10 LRRTM3 rs2147886 202.584 < 0.001
10 LRRTM3 rs2251000 195.167 < 0.001
10 LRRTM3 rs2764807 146.342 < 0.001
10 LRRTM3 rs10762136 101.079 < 0.001
10 VR22 rs11593235 72.618 < 0.001
10 VR22 rs10997591 11.588 0.003
12 A2MP rs16918212 7.025 0.030
12 A2MP rs17804080 10.425 0.005
19 APOE rs440446 67.132 < 0.001  
 
 
Detection of Gene-Gene Interactions in Subsets of Data 
 For each of the three clusters in both the family-based and case-control datasets, 
an MDR gene-gene interaction analysis was conducted.  APOE and the top 5 high-
influence markers, plus the four flanking markers in linkage disequilibrium with those 
top markers, dominated the best MDR models (data not shown).  To allow other effects 
to be detected over these known effects, these ten markers were excluded and the MDR 
analyses were repeated.  Tables 21, 23 and 25 present the best MDR models for clusters 
0, 1 and 2, respectively.  Cross-validation (CV) consistency is provided as the number of 
times (out of 5) that the reported best model was the best in the fold, or split, of the data.  
The average (across all five cross-validation intervals) of the balanced prediction 
accuracy and its corresponding significance level (p-value) is also reported.
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Cluster 0 Results 
 For cluster 0, in the family-based 1DSP dataset, the best one-locus MDR model 
was rs4291 in ACE (p = 0.10) and the best two-locus model was rs4291 in ACE and 
rs7909676 in VR22 (p = 0.17), which is not in LD (r2 ≤ 0.01) with any LRRTM3 marker 
in the dataset (Table 21).  These two models were the only MDR models for cluster 0 that 
achieved a prediction accuracy of approximately 55 percent or greater.  It is worth noting 
that the best one-locus MDR model in the case-control dataset, which had a lower 
prediction accuracy of 48.5 (p = 0.86), was also rs4291 in ACE.  A statistically 
significant full factorial model was fit to the cluster 0 family-based dataset using rs4291 
and rs7909676 (χ2 = 19.264, df=3, p = 0.0002), but the individual parameter estimates 
indicate that the significant effect in the model is primarily coming from marker rs 4291 
(Table 22).  The heterozygote and the A/A homozygote for rs4291 increased risk for 
disease by 2.066 (p = 0.0106). 
 
Cluster 1 Results 
For cluster 1, in the case-control dataset, the best one-locus model was rs3096244 
in VR22 (p = 0.11), which is not in LD (r2 ≤ 0.04) with any LRRTM3 marker in the 
dataset, and the best two-locus MDR model involved rs3096244 in VR22 and rs4343 in 
ACE (p = 0.08).  In the 1DSP family-based dataset, the best two locus model was 
rs2255901 in the chromosome 10 ROI and rs 922347 in VR22 (p = 0.13), which is not in 
LD with any LRRTM3 marker in the dataset,.  These three models were the only MDR 
models for cluster 1 that achieved a prediction accuracy of greater than 55 percent (Table 
23). 
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Table 21.  MDR Analysis Results for Cluster 0 
 
Num 
Loci
Marker Genes 
(Markers)
Avg Bal 
Prediction 
Accuracy p-value
CV 
Consist
Case-
Control 1 ACE (rs4291) 48.50 0.86 2
2 A2MP (rs34362)  PLAU (rs1916341) 52.15 0.34 2
3
VR22 (rs1786927)    
IDE (rs1544210)  
AGT (rs5051)
49.30 0.76 1
1DSP 1 ACE (rs4291) 56.48 0.10 4
2 ACE (rs4291)     VR22 (rs7909676) 54.99 0.17 3
3
ACE (rs4646994)  
OLR1 (rs1050283)   
VR22 (rs4745886)  
48.62 0.87 1
AllDSPs 1 Chr.10 (rs6482044) 54.37 0.12 3
2 OLR1 (rs1050283)  VR22 (rs7909676) 49.42 0.80 1
3
OLR1 (rs1050283)  
CDC2 (rs7919724)  
AGT (rs2148582)
50.54 0.62 1
 
 
 
Table 22.  Logistic Regression Results for Cluster 0 Family-Based Data Using Markers 
from Significant Two-Locus MDR Model 
     95% Hazard  
Confidence  
Ratio  
Limits 
Factor χ2 df p Value Hazard 
Ratio 
Lower Upper 
VR22(rs7909676) 3.6832 1 0.0550 1.916 0.986 3.723 
ACE(rs4291) 6.5254 1 0.0106 2.066 1.184 3.606 
rs7909676 * 
rs4291 
0.3573 1 0.5500 0.881 0.582 1.335 
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Table 23.  MDR Analysis Results for Cluster 1 
 
Num 
Loci
Marker Genes 
(Markers)
Avg Bal 
Prediction 
Accuracy p-value
CV 
Consist
Case-
Control 1 VR22 (rs3096244) 55.74 0.11 3
2 VR22 (rs3096244)  ACE (rs4343) 56.73 0.08 2
3
VR22 (rs3096244)  
VR22 (rs922347)  
PZP (rs3213831)  
53.73 0.24 2
1DSP 1 Chr.10 (rs2255901) 52.61 0.41 3
2 Chr.10 (rs2255901)  VR22 (rs922347) 56.29 0.13 3
3
ACE (rs4646994)  
LRP1 (rs1800154)  
OLR1 (rs1050283)
48.39 0.86 1
AllDSPs 1 GAPDS (rs4806173) 52.74 0.31 4
2 GAPDS (rs4806173)  VR22 (rs7074454) 50.68 0.59 2
3
GAPDS (rs4806173)  
VR22 (rs4745886)  
Chr.10 (rs6482044)
50.51 0.62 1
 
 
 
A statistically significant full factorial model was fit to the cluster 1 case-control 
dataset using rs3096244 in VR22 and rs4343 in ACE from the best two-locus MDR 
model (χ2 = 20.646, df=3, p < 0.001) (Table 24).  Both markers displayed significant 
main effects, and the interaction effect, which had the opposite effect on risk, was also 
significant (Table 24).  At marker rs3096244 in VR22, the heterozygote and T/T 
homozygote decreased risk by 0.464, and at marker rs4343 in ACE, the heterozygote and 
G/G homozygote decreased risk by 0.425.  However, in reference to any genotype 
combination that included the A/A homozygote for rs3096244 or the A/A homozygote 
for rs4343, those same genotypes when considered together actually increased risk by 
1.696. 
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Table 24.  Logistic Regression Results for Cluster 1 Case-Control Data Using Markers 
from Significant Two-Locus MDR Model 
     95% Odds  
Confidence  
Ratio  
Limits 
Factor χ2 df p Value Odds 
Ratio 
Lower Upper 
VR22(rs3096244) 14.498 1 < 0.001 0.464 0.309 0.694 
ACE(rs4343) 14.363 1 < 0.001 0.425 0.270 0.671 
rs3096244 * 
rs4343 
9.072 1 0.003 1.696 1.199 2.400 
 
 
Using the two markers included in the best two-locus MDR model for the 1DSP 
family-based dataset, logistic regression was used to fit a full factorial model to the data.  
However, the full model was not statistically significant (χ2 = 1.4917, df=3, p > 0.68) ; 
nor were any of its factors (data not shown). 
It is perhaps worth noting that in the AllDSPs dataset, rs7074454 and rs4745886 
in VR22 were each in the best two- and three-locus MDR models, respectively.  These 
markers are in linkage disequilibrium with each other in the complete family-based 
dataset but are not in LD with the VR22 markers found in the best case-control MDR 
models.  Marker rs4745886 in VR22 was out of Hardy-Weinberg equilibrium in the 
complete family-based dataset.  None of these family-based models in cluster 1 achieved 
prediction accuracy greater than 55 percent. 
 
Cluster 2 Results 
For cluster 2, the best one-locus MDR model in the case-control dataset was 
rs10997591 in VR22 (p < 0.04), which is not in LD (r2 ≤ 0.12) with any LRRTM3 marker 
in the dataset, and the best one-locus MDR model in the 1DSP family-based dataset was 
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rs11816558 in the ROI on chromosome 10 (p = 0.08).  These two models were the only 
MDR models in cluster 2 that achieved a prediction accuracy of greater than 55 percent 
(Table 25). 
 
 
Table 25.  MDR Analysis Results for Cluster 2 
Num 
Loci
Marker Genes 
(Markers)
Avg Bal 
Prediction 
Accuracy p-value
CV 
Consist
Case-
Control 1 VR22 (rs10997591) 60.09 0.04 5
2 VR22 (rs10997591) CDC2 (1920) 49.49 0.72 1
3
VR22 (rs10997591)  
IDE (rs1544210)  
COG2 (rs3789662)
44.73 0.98 1
1DSP 1 Chr.10 (rs11816558) 59.32 0.08 5
2 OLR1 (rs1050283)  CDC2 (1920) 51.60 0.58 1
3
OLR1 (rs1050283)  
ACE (rs4646994)  
Chr.10 (rs1916341) 
50.15 0.73 1
AllDSPs 1 PZP (rs12230214) 48.03 0.89 1
2 ACE (rs4646994)  Chr.10 (rs870801) 51.98 0.46 1
3
OLR1 (rs1050283)  
ACE (rs4646994)   
CDC2 (rs1920)
47.30 0.93 2
 
 
 
It is worth noting that rs10997591 in VR22 was also present in the best two- and 
three-locus MDR models for the case-control dataset, although their corresponding 
prediction accuracy was below 50 percent.  The marker rs1050283 in OLR1 appeared in 
the best two- and three-locus MDR models for the 1DSP dataset and in the best three-
locus MDR model for the AllDSPs dataset.  In addition, the best two-locus MDR models 
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in both the case-control and the family-based 1DSP datasets and the best three-locus 
model in the family-based AllDSPs dataset, all included marker 1920 in CDC2.  Finally, 
the marker rs4646994 in ACE was included in the best three-locus model for the 1DSP 
dataset and in the best two- and three-locus models for the AllDSPs dataset. 
 
Discussion 
 Simulation studies of the Bayesian Classification method presented in Chapters 
III and IV were performed using simulated case-control data.  The current application of 
the clustering method involves both family-based and case-control data.  Family-based 
data naturally have intrafamily correlations among markers, which may not be relevant to 
the disease in question.  Large families with particular multilocus genotype patterns may 
bias the choice of high influence markers more so than smaller families, leading to 
choices that may not generalize to a large family-based dataset or case-control dataset.  
No attempt was made to control for such intrafamily correlations directly.  However, our 
decision to perform multiple rounds of clustering, choosing only those markers common 
to both datasets, may have averted some of this potential bias.  It is encouraging that, at 
least in this particular application, the same five markers were selected in both the 
family-based and case-control datasets as being the highest influence markers. 
Another issue created by family-based data involves the way in which the 
clustered affected individuals are recombined with the set of unaffected individuals.  
Since the main effect analysis methods for family-based data use pedigree information 
and leverage family structure and intrafamily correlation, any splitting of families 
threatens to reduce the informativeness of such families and to subsequently reduce the 
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power of the analyses.  For this reason, it might have been ideal to have all affected 
individuals from a family always be clustered together, thereby avoiding any disruption 
of family structure.  However, there was no way to implement such constraints within the 
existing (closed source) clustering software, and as it turned out, the clustering method 
did not choose to cluster together all individuals of the same family.  Thus, the power of 
main effect analyses on family-based cluster subsets was likely reduced to some degree. 
The power of our analyses on the cluster subsets may also have been lowered (in 
comparison to the complete datasets) because the number of affected subjects in each 
subset is only a fraction of what is present in the complete dataset.  Since clustering is 
performed only on the affected individuals in the dataset, for the purpose of subset 
analysis, the resulting clusters of affected individuals are recombined with the full set of 
unaffected individuals.  Therefore, this also means that the data in most of the subsets is 
substantially unbalanced.    The complete case-control dataset was already somewhat 
unbalanced, with a ratio of cases to controls of 0.65.  Thus, the ratios in the cluster 
subsets for the case-control data were even more unbalanced—0.31, 0.22 and 0.11—for 
clusters 0, 1 and 2, respectively.  The complete family-based dataset was unbalanced but 
in the opposite direction, with a ratio of cases to controls of 1.91.  Thus, the ratios in the 
cluster subsets for the family-based data were not as badly affected as those in the case-
control dataset—0.90, 0.65, 0.35—for clusters 0, 1 and 2, respectively. 
Another difference between our simulation studies and the current application is 
that the simulation studies used markers which had no linkage disequilibrium (LD) with 
each other, while the current application involved markers with considerable LD, 
comprising multiple haplotype blocks.  The clustering method chose to focus on a set of 
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markers in LRRTM3 that were in high LD with each other to cluster affected subjects 
into more homogeneous subsets.  The fact that the Bayesian Classification method 
essentially used (a readily discoverable) haplotype block to cluster the datasets may not 
be a particularly interesting result.  Afterall, one could have used the results from the 
linkage disequilibrium analysis directly to choose haplotype blocks upon which to stratify 
the data, although the choice among haplotype blocks would have been arbitrary.  
Perhaps the fact that the clustering method could have found other multilocus genotype 
patterns but did not means that there were no other interesting patterns to be found.  
Alternatively, it is possible that there were other multi-locus genotype patterns in the 
datasets but that these patterns simply were not as strong or as consistent as those in the 
haplotype block of LRRTM3 and hence were not chosen to highly influence cluster 
assignment.  One could try to select tag SNPs prior to clustering, with the goal of 
reducing the strength or dominance of such LD in the dataset, thereby allowing other 
weaker, perhaps more interesting, multilocus genotype patterns to be selected for use in 
clustering the dataset.  However, initial attempts at implementing this approach on the 
current datasets indicate that the process of choosing the tag SNPs would be iterative, 
adhoc and somewhat arbitrary—in short, not at all a straight-forward solution to the 
situation.  Additionally, eliminating markers by choosing tag SNPs could also dilute any 
multilocus genotype effects that are present, which the clustering method could have used 
to stratify the data. 
Regardless of whether the clustering method’s use of a haplotype block is novel 
or interesting, the question remains as to whether stratification or clustering based in this 
specific dataset using this particular LD block in LRRTM3 is meaningful.  It is, indeed, 
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possible that there are main effects and/or interactions among other genes that are only 
present on certain LRRTM3 haplotype backgrounds.  It is also possible that there are 
direct or indirect interactions between LRRTM3 and these other genes and that clustering 
on the LRRTM3 haplotype block allows those effects to be detected.  It is also possible 
that the pertinent interactions involve VR22, which is the larger gene in whose intron 
LRRTM3 resides.  Ultimately, whether these results are meaningful will be determined 
by whether the statistical results reported here can be replicated, and, more importantly, 
whether functional molecular studies can demonstrate the biological plausibility of such 
interactions. 
VR22 or CTNNA3 (catenin, alpha 3; MIM#607667) is a binding partner of beta-
catenin (Janssens et al., 2001), which interacts with presenilin 1.  Presenilin 1 interacts 
with the gamma-secretase involved in processing the amyloid precursor protein (APP), 
and its mutations have been associated with increased levels of amyloid beta 42 (Citron et 
al., 1997; Duff et al., 1996; Qian et al., 1998), the primary component of senile plaques 
found in Alzheimer disease.   
Leucine-rich containing proteins, like LRRTM3, are involved in protein-protein 
interactions, and the family of leucine-rich repeat transmembrane proteins (LRRTMs) are 
involved in many cellular events during nervous system development and disease 
(Lauren et al., 2003).  Of particular relevance to Alzheimer disease pathology, LRRTM3 
is highly expressed in the adult mouse hippocampus, in the granular layer of the dentate 
gyrus (Lauren et al., 2003).  Tau-mediated neurodegeneration in this area is thought to 
play a role in Alzheimer disease progression (Shahani et al., 2006). 
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Recent evidence is mounting in support of an alternative hypothesis for 
Alzheimer disease pathology, which implicates cell cycle reactivation as a key early 
event that precedes and possibly is causally related to tau and APP phosphorylation and 
apoptotic cell death (Andorfer et al., 2005; McPhie et al., 2003; Yang et al., 2006).  
Amyloid precursor protein has been purported to regulate activation of neuronal cell 
cycle proteins (McPhie et al., 2003); therefore, hypothetically, mutations in VR22 could 
indirectly affect cell cycle activation, through interactions with APP (by way of beta-
catenin and presenilin 1).  Additionally, since LRRTM3 is thought to be involved in 
neuronal development in some of the key areas that are later targets of neuronal cell death 
in Alzheimer disease, perhaps LRRTM3 is being re-activated in some way that facilitates 
the cell cycle re-entry of neurons.  Thus, it would be interesting to learn whether VR22 
and/or LRRTM3 are differentially expressed in the brains of AD patients versus controls. 
For every cluster, the main effect and interaction subset analyses showed 
LRRTM3 markers exhibiting strong effects.  This is an expected result since almost all 
(affected) individuals in a cluster had the same genotypes at those markers and in 
comparison to the unaffecteds in the datasets, it would appear that those genotypes were 
associated with disease status.  Likewise, flanking or nearby markers in LRRTM3 and the 
larger gene, VR22, within which LRRTM3 resides, might demonstrate effects that could 
be attributed to the LRRTM3 haplotype block effect.  Table 26 shows the NCBI map 
locations of all genotyped markers in the VR22 and LRRTM3 genes, along with their 
HetLOD scores in the complete family-based dataset and its three clusters.  Figure 35 
shows a plot of these HetLOD scores starting with the most distal markers that achieved a 
HetLOD of at least 2. 
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Looking across all the main effect and interaction analyses, there are a few genes 
for each cluster that deserve further investigation in relation to their LRRTM3 haplotype 
(Table 14).  In some cases where there are two or more markers in LD with each other, in 
the case-control dataset, one of the markers is significant but in the family-based dataset, 
the other one is.  This can be a simple case of sampling differences, since the two datasets 
are independent samples drawn from different populations and by chance the distribution 
of alleles or genotypes between affecteds and unaffecteds can be different between those 
samples at any given marker. 
 
Complete Dataset Discussion 
 The preliminary analysis of the complete family-based and case-control datasets 
found three markers that were significant in both the case-control and family-based 
datasets—VR22 markers rs2441718 and rs2456737 and APOE marker rs440446.  
LRRTM3 marker rs1925617 was significant in the case-control dataset and was in LD 
with three other LRRTM3 markers—rs1925622, rs1925632 and rs2764807—which were 
significant in the family-based dataset by their PDT chi-square statistics.  None of the 
MDR interaction analyses that excluded the known effect of APOE produced significant 
models. 
 Many of the markers that were found significant by at least one main effect 
statistical test in either the complete case-control or complete family-based datasets were 
also significant in the analysis of specific subsets produced by the Bayesian Classification  
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Table 26.  Chromosomal Location and Linkage Analysis Results for Markers in VR22 
and LRRTM3.  Highlighted markers were the top five high-influence markers used in the 
final cluster analysis. 
 
HetLOD in Family- Based Dataset
Chrom Gene Marker Location (kb) Complete Cluster 0 Cluster 1 Cluster 2
10 VR22 4783 67,209 0.000 0.900 0.962 0.241
10 VR22 rs1786927 67,352 0.000 1.438 0.338 0.110
10 VR22 rs2126750 67,508 0.036 1.945 1.400 1.617
10 VR22 rs4745886 67,530 0.768 4.702 1.867 0.913
10 VR22 rs7911820 67,534 0.165 4.084 0.490 0.711
10 VR22 rs7070570 67,535 1.366 2.533 3.147 0.241
10 VR22 rs7074454 67,535 0.643 4.952 0.777 1.111
10 VR22 rs10822719 67,535 0.008 0.816 0.380 0.600
10 VR22 rs6480140 67,539 0.000 1.125 0.384 1.857
10 VR22 rs922347 67,653 0.119 1.619 4.590 0.468
10 VR22 rs4463744 67,778 0.551 1.754 2.149 0.413
10 VR22 rs2441718 67,807 1.407 4.043 2.185 3.583
10 VR22 rs2939947 67,808 0.560 3.942 3.634 1.276
10 VR22 rs2456737 67,825 1.038 1.174 3.256 1.468
10 VR22 rs4746606 68,061 0.201 1.251 1.445 1.446
10 VR22 rs7909676 68,105 1.068 3.129 1.772 0.510
10 LRRTM3 rs1001016 68,347 0.000 1.090 0.336 0.000
10 LRRTM3 rs12769870 68,347 0.000 1.843 2.668 0.933
10 LRRTM3 rs1925583 68,350 0.001 0.824 2.681 0.856
10 LRRTM3 rs2394314 68,350 0.015 1.607 2.864 0.852
10 LRRTM3 rs1925577 68,358 0.079 2.224 2.338 0.986
10 LRRTM3 rs10762122 68,386 0.001 0.864 0.820 0.249
10 LRRTM3 rs942780 68,407 0.000 1.880 0.692 0.102
10 LRRTM3 rs1925617 68,435 0.343 11.194 8.205 3.743
10 LRRTM3 rs1925622 68,440 0.302 11.222 9.346 3.917
10 LRRTM3 rs1925632 68,470 0.140 20.293 14.638 8.294
10 LRRTM3 rs1952060 68,473 0.260 12.638 7.820 6.864
10 LRRTM3 rs2147886 68,489 0.066 20.147 16.724 9.664
10 LRRTM3 rs2251000 68,495 0.073 20.409 15.459 9.148
10 LRRTM3 rs2764807 68,499 0.097 13.093 10.721 8.410
10 LRRTM3 rs10762136 68,514 0.492 10.254 10.226 8.366
10 VR22 rs11593235 68,546 0.636 4.803 5.976 6.503
10 VR22 rs10997591 68,672 0.379 2.552 2.550 0.394
10 VR22 rs7903421 68,952 0.000 0.697 0.136 0.812
10 VR22 rs3096244 69,080 0.000 2.521 1.421 0.671  
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analysis.  However, there was not complete consistency across the clusters, and some 
markers were not significant in any of the subsequent main effect analyses of the cluster 
subsets.  Tables 27 and 28 indicate which of the markers initially found significant in the 
complete datasets were also found significant in one or more of the cluster subsets.  Eight 
markers were found significant across all three clusters as well as in their respective 
complete dataset—APOE marker rs440446, two markers from VR22 (rs2441718 and 
rs2456737), four markers from LRRTM3 (rs1925617, rs1925622, rs1925632 and 
rs2764807) and one marker from PLAU (rs2227568).  Interestingly, the effect of APOE 
was less in each of the cluster subsets than it was in the complete datasets, perhaps 
simply due to smaller sample sizes and more unbalanced data.  In contrast, the VR22, 
LRRTM3 and PLAU marker effects were all enhanced in the cluster subsets.  Since the 
clusters were produced basically by stratifying on an LRRTM3 haplotype block, it is not 
surprising that the VR22 and LRRTM3 marker effects are strengthened. 
The PLAU marker rs2227568 is approximately 6.26 Mb away from the nearest 
genotyped VR22 marker and it exhibits no LD (r2=0) with any of the VR22 or LRRTM3 
markers.  Therefore, it is unlikely that the consistency of the PLAU marker’s results can 
be attributed to the LRRTM3 effect.  PLAU (urokinase-type plasminogen activator; 
MIM#5328) converts plasminogen to plasmin, and plasmin is involved in the processing 
of the amyloid precursor protein and in the degradation of amyloid-beta (Finckh et al., 
2003).  The PLAU marker rs2227564 is a C/T missense polymorphism that has been 
associated with plasma amyloid-beta-42 levels and with LOAD in a German sample 
(Finckh et al., 2003) and in a United States Caucasian sample (Ertekin-Taner et al., 
2005).  However, at least two subsequent studies have failed to replicate these results—in  
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Table 27.  Cluster Subset Results for Markers Found Significant in Complete Family-
Based Dataset  (HetLOD > 1, or FBAT or PDT p < 0.05).  Marks in a cluster column 
indicate that the marker was found significant by at least one main effect family-based 
test (linkage, FBAT or PDT) in that cluster subset. 
 
    Cluster  
Chrom Gene Marker 0 1 2 
1 AGT rs5051   x 
10 VR22 rs7070570 x x  
10 VR22 rs2441718 x x x 
10 VR22 rs2456737 x x x 
10 VR22 rs7909676 x x  
10 LRRTM3 rs1925622 x x x 
10 LRRTM3 rs1925632 x x x 
10 LRRTM3 rs2764807 x x x 
10 PLAU rs2227568 x x x 
10 PLAU rs4065 x x  
10 rs4933194   x 
12 A2M rs3832852  x  
12 A2MP rs34362    
12 LRP1 rs1800154 x  x 
12 LRP1 rs9669595 x   
12 LRP1 rs7956957 x   
17 ACE rs4291 x  x 
17 ACE rs4295 x   
17 ACE rs4646994 x   
17 ACE rs4343 x  x 
17 ACE rs4353  x  
17 ACE rs4978 x x  
19 APOE rs440446 x x x 
 
 
 
Table 28.  Cluster Subset Results for Markers Found Significant in Complete Case-
Control Dataset.  Marks in a cluster column indicate that the marker was found 
significant by at least one main effect family-based test (linkage, FBAT or PDT) in that 
cluster subset. 
 
    Cluster  
Chrom Gene Marker 0 1 2 
10 CDC2 rs2448347  x  
10 VR22 rs1786927    
10 VR22 rs2441718    
10 VR22 rs2456737    
10 LRRTM3 rs942780    
10 LRRTM3 rs1925617 x x x 
12 GAPD rs1060621    
19 APOE rs440446 x x x 
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an Italian sample (Bagnoli et al., 2005) and in a Scottish and Swedish sample (Blomqvist 
et al., 2004). 
 
Cluster 0 Discussion 
For cluster 0, three genes (PLAU, IDE and ACE) showed interesting results for 
main effect and/or interaction analyses.  In PLAU, the marker rs2227568 was significant 
according to both its two-point HetLOD score and its Pearson chi-square statistic.  The 
PLAU markers rs2227564 and rs2227566, which are in LD with the former marker, were 
also significant by their HetLOD scores. 
IDE (insulin degrading enzyme; MIM#146680) is a metallopeptidase that can 
degrade peptides such as amyloid beta and may be responsible for the removal of 
extracellular amyloid beta (Selkoe, 2001) and the clearance of the cytoplasmic fragment 
of amyloid precursor protein following liberation of the amyloid-beta protein (Edbauer et 
al., 2002).  In IDE, the marker rs7099761 was significant by its HetLOD score and its 
Pearson chi-square statistic.  The IDE marker rs1544210, which is in LD with the former 
marker, was also significant by its Pearson chi-square statistic. 
Perhaps the most interesting results were for the ACE gene.  ACE (angiotensin 1 
converting enzyme; MIM#106180) has been shown to inhibit the aggregation of amyloid 
beta by degrading amyloid beta 40 into less toxic products (Hu et al., 1999; Hu et al., 
2001).  The marker rs4291 was significant by its PDT, FBAT and Pearson chi-square 
statistics and appeared in the best one- and two-locus MDR models for the 1DSP family-
based dataset.  This two-locus MDR model was confirmed by logistic regression to be 
largely a main effect of rs4291.  Five other ACE markers—rs4295, rs4311, rs4646994, 
125 
rs4343 and rs4978—which were all in LD with the former marker and/or each other, 
were also significant by their PDT and FBAT statistics. 
 
Cluster 1 Discussion 
For cluster 1, four genes (PLAU, IDE, CDC2 and ACE) showed interesting 
results for main effect and/or interaction analyses.  In PLAU, markers rs1916341, 
rs2227566 and rs4065, which are in LD with each other, were all significant by their 
HetLOD scores and Pearson chi-square statistics.  In IDE, marker rs1832186 was 
significant by its FBAT, PDT and Pearson chi-square statistics.  In addition, IDE markers 
rs2251101 and rs4646954, which are in LD with rs1832186, were also significant by 
their FBAT and PDT chi-square statistics. 
CDC2 (cell division cycle 2; MIM#116940) is a kinase involved in the abnormal 
phosphorylation of tau and the aggregation of tau into paired helical filaments (Pei et al., 
2006), which are present in the neurofibrillary tangles of Alzheimer disease.  In CDC2, 
markers rs2448347 and 1920 were significant by their HetLOD scores and their Pearson 
chi-square statistics.  Another CDC2 marker, rs2448341, which is in LD with rs2448347, 
was also significant by its Pearson chi-square statistics and its PDT chi-square statistic. 
Finally, in ACE, markers rs4646994 and rs4343, which are in LD with each other, 
were significant by their Pearson chi-square statistics, and rs4343 appeared in the best 
two-locus MDR model in the case-control dataset, which was confirmed by logistic 
regression to have both a main and interactive effect involving rs4343.  In addition, ACE 
markers rs4353 and rs4978, which are in LD with rs4646994, were found significant by 
their PDT chi-square statistics. 
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Cluster 2 Discussion 
In cluster 2, there were no genes, other than the expected LRRTM3, VR22 and 
APOE, which showed evidence for association in both the case-control and family-based 
datasets.  This subset was the smallest and most unbalanced from each of the case-control 
and family-based clusters, and it is possible that its overall size and/or the extent of the 
imbalance between affecteds and unaffecteds made these analyses too underpowered to 
detect an effect, if it were there.  It is also possible that no interactions exist with the 
cluster 2 LRRTM3 haplotype and the other markers included in the datasets. 
 
Other Discussion 
 No discussion about a large data analysis project such as this would be complete 
without mention of the multiple-testing problem.  As one increases the number of tests 
performed, the likelihood of generating false positive results also increases, beyond the 
per-comparison significance level (alpha) established at the beginning of the study.  
There are a number of different strategies for correcting for this inflation of the false 
positive rate.  However, most are quite conservative, and in light of the fact that the 
current study is exploratory in nature, such caution at the expense of power would be 
imprudent.  For example, if we were to use a simple Bonferoni correction (Dunn OJ, 
1961), we would have to divide our per-comparison alpha by the total number of markers 
being tested (93 for the case-control dataset and 138 for the family-based dataset), 
resulting in a family-wise alpha of about 0.0005.  In the overall datasets, only APOE 
marker rs440446 would have been considered statistically significant, and in the cluster 
subsets, only a few other LRRTM3 markers would have reached significance also.  A 
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more liberal correction strategy such as False Discovery Rate could be employed instead 
(Benjamini and Hochberg, 1995; Storey, 2002).  However, since our predominant goal is 
to not miss any real effects, which we could subsequently investigate further, even a 
slightly more liberal correction strategy is not desired.  In addition, since we know there 
is considerable LD among our markers, the assumption that all the tests are independent 
is not valid.  We would, in fact, expect that two markers in LD with each other would 
frequently produce similar results, in excess of how often two independent markers 
should do so.  Furthermore, since all of the markers tested were chosen because they are 
functional and/or positional candidates for late-onset Alzheimer disease, the likelihood 
that a positive result is true is higher than it would be if the markers were chosen at 
random, for example in the case of a genomic screen.  Finally and perhaps most 
importantly, it should be noted that we have tested two independent datasets, which serve 
as one test and one replication dataset, and are focusing only on those effects that were 
found significant (at the per-comparison level of 0.05) in both datasets.  Thus, we have 
further reduced the chance that such a statistically significant result is a false positive. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary, Conclusions and Future Studies 
 Common diseases with a genetic basis are likely to have a very complex etiology, 
in which the mapping between genotype and phenotype is far from straightforward.  A 
new comprehensive statistical and computational strategy for identifying the missing link 
between genotype and phenotype has been proposed.  Numerous examples of 
heterogeneity and gene-gene or gene-environment interactions support the theoretical 
basis for such an approach, which emphasizes the need to address heterogeneity in the 
first stage of any analysis (Chapter II).  Uncovering any heterogeneity that may exist in a 
dataset removes a formidable source of noise, affording main effect and interaction 
analysis methods the best opportunity to detect effects that may be present only on 
particular genetic backgrounds or in individuals with particular environmental 
exposure(s). 
It is a reality that currently a majority of genetic studies, particularly those 
involving neurological diseases, do not have substantial phenotypic data available, even 
though the quality and volume of genotypic data may be excellent.  Many factors, 
including cost, feasibility (invasiveness), and technical limitations (reliability and 
interpretation) of phenotyping technologies, make the collection of rich phenotypic data 
more challenging.  Given the lack of methods for dissecting heterogeneity that do not rely 
on substantial phenotypic data, a comparison of three ‘unsupervised’ clustering methods 
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was conducted (Chapter III).  Bayesian Classification was chosen as the best of these 
methods, which allow detection of multilocus genotype patterns that may underlie or be a 
proxy for genetic or trait heterogeneity.  It performed very well under a simple genetic 
model of trait heterogeneity, and it had very good control of its false positive rate and 
acceptably low false negative rates under specific simulation conditions. 
Since it is unknown how complex the genetic models in real data are, a further 
evaluation was conducted of Bayesian Classification’s performance and applicability 
under a wider range of simulation conditions was performed (Chapter IV).  False positive 
rates were well-controlled under all conditions simulated.  However, false negative rates 
varied dramatically between conditions.  Under the specific condition of having a 
relatively high number of nonfunctional loci (100) and a moderate sample size (500 
affected individuals), the false negative rates were unacceptably high (at or above 60 
percent).  However, for all other conditions, the false negative rates were at or below 20 
percent, with most below five percent (at an alpha of ten percent).  The other number of 
nonfunctional loci tested was an order of magnitude lower (10), and the other value for 
sample size was double (1000).  Thus, further simulation studies exploring the 
“breakpoint” or slope of the false negative rates between the two extremes of the current 
simulation conditions may further aid in interpretation of negative results.  For example, 
there may be a critical ratio of independent variables (genotypes) to instances 
(individuals) above 5 affecteds per marker genotyped that must be maintained in order to 
keep false negative rates under control, and this would be an important to know when 
designing a study or interpreting results from a Bayesian Classification analysis. 
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The application to late-onset Alzheimer disease presented in Chapter V involves a 
family-based dataset with 138 markers genotyped and 1422 affected individuals (yielding 
a ratio of over 10 affecteds per marker genotyped) and a case-control dataset with 93 
markers genotyped and 451 affected individuals (yielding a ratio of just under 5 affecteds 
per marker genotyped).  Thus, based on the simulation studies, the case-control dataset 
may have been underpowered to allow detection of heterogeneity by the Bayesian 
Classification method.  However, this concern was perhaps mitigated by taking a 
consensus approach, looking for commonality of high-influence markers between the two 
datasets. 
 Bayesian Classification found statistically significant clusterings for both the 
family-based and case-control datasets, which used the same five markers as their most 
influential in determining cluster assignment.  These markers were all in LRRTM3 and 
were in high linkage disequilibrium with each other.  Each of the three resulting clusters 
could be characterized by their haplotypes at these five markers, and the same haplotypes 
defined the clusters in both the family-based and case-control data.  In subsequent 
analyses to detect main effects and gene-gene interactions, markers in four genes—
PLAU, IDE, CDC2 and ACE—were found to be associated with late-onset Alzheimer 
disease in particular subsets of the data based on their LRRTM3 haplotype.  While all of 
these genes are viable candidates for LOAD based on their known biological function, 
further studies are needed to replicate these statistical findings and to elucidate possible 
biological interaction mechanisms between LRRTM3 and these genes. 
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Future Directions for Research 
Molecular biologists and geneticists alike now acknowledge that the most 
common human diseases with a genetic component are likely to have complex etiologies. 
Similarly, there has been increasing appreciation for the phenotypic complexity of 
disease traits and for the need to collect rich phenotypic data to facilitate the elucidation 
of the even more complex relationships between genotypes and phenotypes. Investigation 
of such complexity requires well-informed study design, meticulous data collection and 
innovative strategies for data analysis. 
Over the past twenty years, advances in genotyping technology have far outpaced 
those in statistical and computational methods for analyzing genetic data.  Likewise, 
geneticists have given much less attention to phenotyping technologies.  To most 
effectively leverage the massive amounts of genotypic data being produced, we must 
have comparably rich datasets of phenotypic information available for mapping 
genotypes to phenotypes.  Thus, going forward, genetic studies will need to increasingly 
focus time and resources to collecting phenotypic data that can refine definitions or 
subcategories of traits or diseases and can serve as endophenotypes, which are more 
likely to have simple etiologies and to directly map to specific genetic markers. 
In the case of neurological diseases, one collection of phenotyping technologies 
which has matured considerably over the past five to ten years is neuroimaging.  
Magnetic resonance imaging (MRI) and positron emission tomography (PET) have been 
used successfully to detect signs of disease, sometimes in advance of clinical symptoms, 
in such neurological diseases as Alzheimer disease (Masters et al., 2006; Small et al., 
2000) schizophrenia (Ho et al., 2003; Velakoulis et al., 2006) and Tourette syndrome 
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(Gerard and Peterson, 2003).  The more recently developed diffusion tensor imaging 
(DTI) method might come even closer to measuring a biologically relevant proxy for 
neuronal dysfunction, and it has already been applied to such neurological diseases as 
Alzheimer disease (Nierenberg et al., 2005), schizophrenia (Buchsbaum et al., 2006) and 
Turner syndrome (Holzapfel et al., 2006).  Neuroimaging methods are minimally 
invasive and can produce data with good spatial or temporal resolution.  Voxel-based 
morphometry methods are being developed and applied for associating differences in 
activation of particular brain regions with genetic markers of disease. 
In addition to these neuroimaging technologies, an emphasis on possible 
biological mechanisms of disease has positively influenced the design of behavioral 
assessment tools, increasing their utility for phenotyping and producing endophenotypes 
that can be mapped to genotypic data.  Overall, careful planning of study designs will be 
essential, making best use of existing resources and keeping in mind what statistical and 
computational analyses will be possible based on the types of data to be collected.  Future 
genetic studies of neurological diseases will require collaboration among geneticists, 
behavioral neuroscientists and neuroimaging experts, particularly in the short-term.  
Methodologies enabling the integration of disparate data sources (genotyping and 
neuroimaging or behavioral) must be investigated in order to harness the power inherit in 
their complexity. 
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